The clinical effectiveness and cost-effectiveness of vinorelbine for breast cancer: A systematic review and economic evaluation

Health Technology Assessment

Volumn 6, Issue 14, 2002, Pages

  Lewis, R ^a   Bagnall, A M ^a   King, S ^a   Woolacott, N ^a   Forbes, C ^a   Shirran, L ^a   Duffy, S ^a   Kleijnen, J ^a   Ter Riet, G ^b   Riemsma, R ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BRONCHODILATING AGENT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; ONDANSETRON; PACLITAXEL; TRASTUZUMAB; VINCA ALKALOID;

ABDOMINAL PAIN; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANGINA PECTORIS; ANOREXIA; AREFLEXIA; ARTHRALGIA; ASTHENIA; AUTONOMIC NEUROPATHY; BLOOD TOXICITY; BONE PAIN; BRAIN DISEASE; BRAIN INJURY; BREAST CANCER; BURN; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DEEP VEIN THROMBOSIS; DIAPHRAGM DISEASE; DIARRHEA; DISEASE COURSE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; ECONOMIC EVALUATION; EPIGASTRIC PAIN; ERYTHROCYTE TRANSFUSION; EYE DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLU LIKE SYNDROME; FLUID RETENTION; FUNCTIONAL DISEASE; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; HYPESTHESIA; HYPOTENSION; INFECTION; INJECTION PAIN; LEUKOPENIA; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TOXICITY; LUNG TOXICITY; MALAISE; MAXIMUM TOLERATED DOSE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; MYALGIA; NAIL DISEASE; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; PAIN; PANCREATITIS; PARALYTIC ILEUS; PARESTHESIA; PELVIS PAIN SYNDROME; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHLEBITIS; PHOTOSENSITIVITY; PNEUMONIA; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SENSORY NEUROPATHY; SEPSIS; SEPTIC SHOCK; SEPTICEMIA; SIDE EFFECT; SKIN DISEASE; SKIN IRRITATION; STOMATITIS; TASTE AVERSION; THORAX PAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TOXICITY; TREATMENT FAILURE; VEIN DISEASE; VEIN THROMBOSIS; VOMITING; XEROSTOMIA;

EID: 0036926764     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta6140     Document Type: Review

References (415)

1. Clinical Evidence: A Compendium of the Best Available Evidence for Effective Health Care. Issue 3. London: BMJ Publishing Group; 2000.
2. Office for National Statistics. Mortality Statistics: Cause. Review of the Registrar General on Deaths by Cause, Sex and Age, in England and Wales, 1999. London: The Stationery Office; 2000.
3. Cancer Research Campaign. CancerStats: Mortality: UK [monograph online]. London: Cancer Research Campaign, 2000. [cited 2000 Oct 27]. URL: http://www.crc.org.uk/cancer/pageimages/csmortality.pdf
4. Iselius L, Slack J, Littler M, Morton NE. Genetic epidemiology of breast cancer in Britain. Ann Hum Genet 1991;55:151-9.
5. Chappuis PO, Rosenblatt J, Foulkes WD. The influence of familial and hereditary factors on the prognosis of breast cancer. Ann Oncol 1999;10:1163-70.
6. Northern Yorkshire Cancer Registry and Information Service. Northern and Yorkshire Cancer Networks: A Report on Incidence and Management for the Main Sites of Cancer 1998. Leeds: Northern and Yorkshire Cancer Registry and Information Service, The Leeds Teaching Hospitals NHS Trust; 2001.
7. Lamb H, Wiseman L. Docetaxel: A pharmacoeconomic review of its use in the treatment of metastatic breast cancer. Pharmacoeconomics 1998;14:447-59.
8. Roche. Herceptin (Trastuzumab) NICE Submission: Achieving Clinical Excellence in the Treatment of Metastatic Breast Cancer. Roche submission to the National Institute for Clinical Excellence. Welwyn Garden City: Roche; December 2000.
9. Ledermann J, Brown J, Ranson M. What is the cost-effectiveness of trastuzumab therapy for metastatic breast cancer? In: National Coordinating Centre for Health Technology Assessment (NCCHTA) Pharmaceutical Panel Vignette. Southampton: NCCHTA; 1999.
10. Fornier M, Munster P, Seidman AD. Update on the management of advanced breast cancer. Oncology (Huntingt) 1999;13:647-58.
11. Pierre Fabre Ltd. The Clinical and Cost Effectiveness of Navelbine (Vinorelbine) in the Treatment of Breast Cancer: Sponsor Submission to the National Institute for Clinical Excellence. Winchester: Pierre Fabre Ltd; 2000.
12. Abeloff MD. Vinorelbine (Navelbine) in the treatment of breast cancer: A summary. Semin Oncol 1995;22 (2 Suppl 5): 1-4.
13. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. Issue 39. London: BMA; 2000.
14. Thall PF, Simon RM. Recent developments in the design of Phase II clinical trials. Cancer Treat Res 1995;75:49-71.
15. Egger M, Davey Smith G, Altman D, editors. Systematic Reviews in Health Care: Meta-analysis in Context. 2nd ed. London: BMJ Publishing Group; 2001.
16. Altman D. Practical Statistics for Medical Research. 2nd ed. London: Chapman & Hall; 1999.
17. Birch S, Gaffni A. Cost-effectiveness and cost utility analyses: Methods for the non-economic evaluation of healthcare programs and how we can do better. Massachusetts: Kluwer Academic Publishers; 1996.
18. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford: Oxford Medical Publications; 1997.
19. Bruno S, Puerto VL, Mickiewicz E, Hegg R, Texeira LC, Gaitan L, et al. Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy: The Latin-American experience. Am J Clin Oncol 1995;18:392-6.
20. Delgado FM, Canobbio L, Boccardo F, Brema F, Fosser V. Phase II pilot study of Navelbine in advanced breast cancer. In: Navelbine (Vinorelbine): Update and New Trade. Montrouge: John Libbey Eurotext Ltd; 1991. p. 199-207.
21. Fumoleau P, Delgado FM, Delozier T, Monnier A, Delgado MAG, Kerbrat P, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245-52.
22. Garcia Conde J, Lluch A, Martin M, Casado A, Gervasio H, De Oliveira C, et al. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994;5:854-7.
23. Kesselring GLF, Hegg R, Tosello C, Delgado G, Teixeira LC, Aguiar LF, et al. Phase II trial of the Navelbine (NVB) in the treatment of advanced breast cancer (ABC) in Brazil [meeting abstract]. Int J Gynecol Obstet 1991;Suppl:147.
24. Queisser W, Doss A, Wander HE, Bremer K, Becher R, Rieche K, et al. Phase II study of vinorelbine by oral route (in a hard gelatine capsule) for metastatic breast cancer patients: A trial of the Phase I/II study group of the Association for Medical Oncology of the German Cancer Society. Onkologie 1991;14:35-9.
25. Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriguez R, Cuevas MA, et al. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994;12:336-41.
26. Smith IE. Navelbine in combination chemotherapy for advanced breast cancer. J Cancer Res Clin Oncol 1990;116 Suppl 2:1052.
27. Terenziani M, Demicheli R, Brambilla C, Ferrari L, Moliterni A, Zambetti M, et al. Vinorelbine: An active, non cross-resistant drug in advanced breast cancer: Results from a Phase II study. Breast Cancer Res Treat 1996;39:285-91.
28. Toussaint C,Izzo J, Spielmann M, Merle S, May Levin F, Armand JP, et al. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. J Clin Oncol 1994;12:2102-12.
29. Twelves CJ, Dobbs Na, Curnow A, Coleman RE, Stewart AL, Tyrrell CJ, et al. A Phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer 1994;70:990-3.
30. Vogel C, O'Rourke M, Winer E, Hochster H, Chang A, Adamkiewicz B, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999;10:397-402.
31. Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 1995;13:2722-30.
32. Winer E, O'Rourke M, Vogel C, Overmoyer B, Blumenreich M, Pendergrass K, et al. A US multicenter Phase II trial of oral Navelbine in elderly women with advanced breast cancer. Breast Cancer Res Treat 1993;27:136.
33. Venturino A, Comandini D, Simoni C, Merlini L, Naso C, Palumbo R, et al. Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A Phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin. Breast Cancer Res Treat 2000;60:195-200.
34. Brown RE, Hutton J, Burrell A. Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 2001;19:1091-102.
35. Silberman G, Gupta S, Berkowitz N, Leyland Jones B. Cost-effectiveness of capecitabine, continuous infusion 5-FU, gemcitabine and vinorelbine in the treatment of metastatic breast cancer [meeting abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta, GA, USA. Alexandria, VA: ASCO; 1999. A1629.
36. Launois R, Reboul Marty J, Henry B, Bonneterre J. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer: Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics 1996;10:504-21.
37. Leung PP, Tannock IF, Oza AM, Puodziunas A, Dranitsaris G. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol 1999;17:3082-90.
38. Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995;13:2567-74.
39. Blajman C, Balbiani L, Block J, Coppola F. Chacon R, Fein L, et al. A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma. Cancer 1999;85:1091-7.
40. Namer M, Soler Michel P, Turpin F, Chinet Charrot P, De Gislain C, Pouillart P, et al. Results of a Phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer. Eur J Cancer 2001;37:1132-40.
41. Norris B, Pritchard KI, James K, Myles J, Bennett K, Marlin S, et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 2000;18:2385-94.
42. Alvarez A, Balbiani L, Block J, Temperley G, Chacon R, Capo A, et al. Phase II study: Navelbine (NVB) + adriamycin (A) as first line chemotherapy in advanced breast cancer (ABC). Ann Oncol 1994; 5 Suppl 8:33.
43. Baltali E, Firat D, Icli F, Berk O,Uskent N, Danel P, et al. Navelbine (NVB) doxorubicin (DX) combination (D1-D8) in advanced breast carcinoma (ABC) previously untreated. Breast Cancer Res Treat 1996;41:286.
44. Coppola F, Balbiani L, Blajman C, Vilanova P, Bonicatto S, Rufino C, et al. Vinorelbine (VNB) containing regimens in three different schedules for the treatment of advanced breast cancer (ABC) [meeting abstract]. Proceedings of the 30th Annual Meeting of the American Society of Clinical Oncology; 1994 May 14-17; Dallas, TX, USA. Alexandria, VA: ASCO; 1994. A144.
45. Hegg R, Costa MA, Perdicaris M, Delgado GL, Cabral Filho S, Malyzner A, et al. A Phase II trial of fractionated vinorelbine/doxorubicin as first-line therapy for advanced breast cancer. Curr Med Res Opin 2001;16:225-34.
46. Hochster HS, Vogel CL, Burman SL, White R. Activity and safety of vinorelbine combined with doxorubicin or fluorouracil as first-line therapy in advanced breast cancer: A stratified Phase II study. Oncologist 2001;6:269-77.
47. Siedlecki P, Le Bras F, Pawlicki M, Zaluski J, Ramlau C, Rolski J, et al. A multicenter Phase II study of Navelbine (NVB) and doxorubicin (DOX) as first line chemotherapy in advanced breast cancer (ABC). Eur J Gynaecol Oncol 1997;18:293.
48. Smalley R, Craig J, Jones S, Hohneker J. Navelbine (NVB) and adriamycin (DOX) in combination for advanced breast cancer: Phase I-II evaluation of a new schedule [meeting abstract]. Proceedings of the 17th Annual San Antonio Breast Cancer Symposium on Breast Cancer Research and Treatment; 1994 Dec 8-10; San Antonio, TX, USA. p. 66.
49. Spielmann M, Dorval T, Turpin F, Antoine E. Jouve M, Maylevin F, et al. Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 1994;12:1764-70.
50. Vorobiof D, Goedhals L, Barnardt P, Gudgeon A, Van Der Merwe A, Smith L, et al. Phase II study of IV Navelbine (NVB) and doxorubicin (DOX) in previously untreated advanced breast cancer (ABC) [meeting abstract]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology; 1997 May 17-20; Denver, CO, USA. Alexandria, VA: ASCO; 1997. A693.
51. Baldini E, Tibaldi C, Chiavacci F, Di Lieto M, Fioretto L, [Giallom Bardo] A, et al. Epirubicin/vinorelbine as first line therapy in metastatic breast cancer. Breast Cancer Res Treat 1998;49:129-34.
52. Cottu P, Giacchetti S, Espire M, Fixtra JM, Mignot L, Morvan F, et al. A Phase II study with vinorelbine (NVB) and epirubicin (E) in metastatic breast cancer (MBC). Breast Cancer Res Treat 1993;27:146.
53. Ezzat A, Motawy S, Berry J, Attia N. Pilot study of Navelbine (NVB) and epirubicin (EPR) for the treatment of inoperable locally advanced and metastatic breast cancer. Breast Cancer Res Treat 1996;41:286.
54. Nistico C, Garufi C, Barni S, Frontini L, Galla DA, Giannarelli D, et al. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: A high-activity, dose-dense weekly regimen for advanced breast cancer. Ann Oncol 1999;10:937-42.
55. Tabiadon D, Zonato C, Frontini L, Barni S, Biazoli R, Valsecchi R, et al. Multicentric Phase II study with vinorelbine (VNB) and epirubicin (EPI) as first line chemotherapy in metastatic breast cancer (MBC): Preliminary data [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 15-18; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A679.
56. Vici P, Amodio A, Lauro LD, Colucci G, Giotta F, Pezzella G, et al. A multicentric Phase II trial of vinorelbine (VNB) and epirubicin (EPI) as first line chemotherapy in metastatic breast cancer (MBC): Preliminary data [meeting abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta, GA, USA. Alexandria, VA: ASCO; 1999. A437.
57. Ibrahim NK, Buzdar AU, Valero V, Dhingra K, Willey J, Hortobagyi GN. Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer 2001;91:664-71.
58. Martin M. Phase II study of paclitaxel plus vinorelbine in metastatic breast cancer patients with prior anthracycline exposure. Semin Oncol 1999;26(1 Suppl 2):30.
59. Martin M, Lluch A, Casado A, Garciia Carbonero I, De Paz L, Esteban C, et al. Paclitaxel plus vinorelbine: An active regimen in metastatic breast cancer patients with prior anthracycline exposure. Ann Oncol 2000;11:85-9.
60. Romero Acuna L, Langhi M, Perez J, Romero Acuna J, Machiavelli M, Lacava J, et al. Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 1999;17:74-81.
61. Vici P, Amodio A, Di Lauro L, Conti F,Gionfra T, Belli F, et al. First-line chemotherapy with vinorelbine and paclitaxel as simultaneous infusion in advanced breast cancer. Oncology 2000;58:3-7.
62. Ferrero JM, Pivot X, Namer M, Wendling JL, Frenay M, Francois E, et al. Combination of mitoxantrone-vinorelbine as first-line chemotherapy for metastatic breast carcinoma. Bull Cancer 1995;82:202-7.
63. Frasci G, Comella G, Comella P, Salzano F, Cremone L, Della Volpe N, et al. Mitoxantrone plus vinorelbine with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer patients: A dose and schedule finding study. Breast Cancer Res Treat 1995;35:147-56.
64. Gladieff L, Houyau P, Mihura J, Martinez M, Caunes N, Chevreau C, et al. A Phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women. Bull Cancer 1996;83:703-6.
65. Llombart Cussac A, Pivot X, Rhor Alvarado A, Le Cesne A, Le Chevalier T, Tursz T, et al. First-line vinorelbine-mitoxantrone combination in metastatic breast cancer patients relapsing after an adjuvant anthracycline regimen: Results of a Phase II study. Oncology 1998;55:384-90.
66. Bonneterre J, Cuvier C, Bonneterre ME, Marty M, Soares A, Assadourian S. Dose-finding study of docetaxel (Taxotere) and vinorelbine (Navelbine) D1 and D8 1st-line chemotherapy for metastatic breast cancer (MBC) [meeting abstract]. Proceedings of the 89th Annual Meeting of the American Association for Cancer Research; 1998 Mar 28-Apr 1; New Orleans, LA, USA. Philadelphia, PA: AACR; 1998. p. 320.
67. De Paz L, Lluch A, Martin M, Garcia Carbonero I, Azagra P, Chirivella I, et al. A Phase II study of docetaxel (D) and vinorelbine (V) in metastatic breast cancer (MBC) [meeting abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta, GA, USA. Alexandria, VA: ASCO; 1999. A452.
68. Fumoleau P, Fety R, Delecroix V, Perrocheau G, Azli N. Docetaxel combined with vinorelbine: Phase I results and new study designs. Oncology (Huntingt) 1997;11(6 Suppl 6):29-31.
69. Kornek GV, Ulrich Pur H, Penz M, Haider K, Kwasny W, Depisch D, et al. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 2001;19:621-7.
70. Dieras V, Extra JM, Bellissant E, Espie M, Morvan F. Pierga JY et al. Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: Results of a Phase II study using a sequential group method. J Clin Oncol 1996;14:3097-104.
71. Kornek GV, Haider K, Kwasny W, Lang F, Krauss G, Hejna M, et al. Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and L-leucovorin plus human granulocyte colony-stimulating factor. Br J Cancer 1998;78:673-8.
72. Nole F, De Braud F, Aapro M, Minchella I, De Pas M, Zampino MG, et al. Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: A regimen with a low subjective toxic burden. Ann Oncol 1997;8:865-70.
73. Dieras V, Cottu P, Kalla S, Beuzeboc P, Palangie T, Jouve M, et al. Phase II study of association of i.v. Navelbine (NVB), 5-fluorouracil (5FU) and doxorubicin (DX) as first line treatment of patients with advanced breast cancer (ABC). Breast Cancer Res Treat 1996;37 Suppl:75.
74. Goss PE, Fine S, Gelmon K, Rudinskas L, Ottaway J, Myles J, et al. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer. Cancer Chemother Pharmacol 1997;41:53-60.
75. Ardavanis A, Extra JM, Cuvier C, Marty M. Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer. In Vivo 1998;12:559-62.
76. Turpin F, Lluch A, Closon MH, Gruia G, Llombart A, Fernandez R, et al. Treatment with a nonanthracycline regimen in advanced breast cancer: Vinorelbine, cyclophosphamide, and 5-fluorouracil with folinic acid. Am J Clin Oncol 1999;22:196-8.
77. Braud AC, Jauffret E, Thirion P, Feuilhade F, Piedbois P, Brun B, et al. Phase II study of vinorelbine, epirubicin and cyclophosphamide (NEC) as first line chemotherapy in patients with metastatic breast cancer (MBC): Preliminary results [meeting abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta, GA, USA. Alexandria, VA: ASCO; 1999. A433.
78. Esteban E, De Sande G, Puertas J, Fra J, Palacio I, Vieitez JM, et al. A Phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer. Breast Cancer Res Treat 2000;62:127-33.
79. Audhuy B, Husseini F, Dreyfus B, Fruge F, Guiochet N, Vuillemin E, et al. Phase II trial of Navelbine (NVB) and cisplatin (CDDP) in first line chemotherapy of metastatic breast cancer (MBC) [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 15-18; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A487.
80. Hochster H, Wasserheit C, Siddiqui N, Sorich J, Downey A, Wernz J, et al. Vinorelbine/cisplatin therapy of locally advanced and metastatic breast cancer: An active regimen [meeting abstract]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology; 1997 May 17-20; Denver, CO, USA. Alexandria, VA: ASCO; 1997. A606.
81. Haider K, Kornek GV, Kwasny W, Weinlander G, Valencak J, Lang F, et al. Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor. Breast Cancer Res Treat 1999;55:203-11.
82. Leone BA, Vallejo CT, Romero AO, Perez JE, Cuevas MA, Lacava JA, et al. Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2993-9.
83. Kornek GV, Haider K, Kwasny W, Hejna M, Raderrer M, Meghdadi S, et al. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor. Br J Cancer 1996;74:1668-73.
84. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-30.
85. Nole F, Munzone E, Mandala M, Catania C, Orlando L, Zampino MG, et al. Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: A Phase II study. Ann Oncol 2001;12:95-100.
86. Guler N, Yucel I, Ozet A, Bilkay BC, Erkisi M, Onur H, et al. Vinorelbine (N), epirubicin (E) and 5-fluorouracil (F) combination in the first-line treatment of metastatic breast carcinoma (MBC) [meeting abstract]. Proceedings of the 2nd European Breast Cancer Conference; 2000 Sept 26-30; Brussels, Belgium. Brussels: Federation of European Cancer Societies; 2001. S90.
87. Kakolyris S, Kourousis C, Koukourakis M, Androulakis N, Vamvakas L, Agelaki S, et al. First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. Am J Clin Oncol 1999;22:568-72.
88. Wendling JL, Nouyrigat P, Vallicioni D, Cals L. Cisplatin (CDDP)-mitoxantrone (MTZ)-vinorelbine (VNR) as first line chemotherapy (CT) for metastatic breast cancer: A pilot study [meeting abstract]. Proceedings of the 31st Annual Meeting of the American Society of Clinical Oncology; 1995 Mar 20-23; Los Angeles, CA, USA. Alexandria; VA, ASCO; 1995. A266.
89. Subramanyan S, Abeloff MD, Bond SE, Davidson NE, Fetting JH, Gordon GB, et al. A Phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer. Cancer Chemother Pharmacol 1999;43:497-502.
90. Bonicatto S, Lozano M, Polera J, Rosembrock C, Fein L, Gil Deza E, et al. Phase II study of a new time schedule: Navelbine (NVB) plus doxorubicin (DOX) in advanced breast cancer (ABC): Preliminary report [meeting abstract]. Proceedings of the 8th International Congress on Anti-Cancer Chemotherapy; 1998 Feb 3-6; Paris, France. Paris: Service d'Oncologie Medicale Pitie-Salpetriere; 1998, p. 155.
91. Arca R, Fernandez E, Ivulich C, Lazaris C, Lopez J, Lozano M, et al. Navelbine (NVB) + doxorubicin (DOX) as first line chemotherapy in metastatic breast cancer (MBC) [meeting abstract]. Proceedings of the 8th International Congress on Anti-Cancer Treatment; 1998 Feb 3-6; Paris, France. Paris: Service d'Oncologie Medicale Pitie-Salpetriere; 1998. p. 116.
92. Monnier A, Bonneterre J, Roche H, Fargeot P, Namer M, Gustalla PJ, et al. Phase III study: Taxotere (TXT) versus 5-fluorouracil + Navelbine (FUN) in patients (pts) with metastatic breast cancer (MBC) as 2nd line chemotherapy (CT) (preliminary results). Ann Oncol 1998;9 Suppl 4:12.
93. Frasci G, Comella R, D'Aiuto G, Thomas R, Capasso I, Elmo M, et al. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: A parallel dose-finding study. Ann Oncol 2000;11;367-71.
94. Aapro MS. Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer. Oncology (Huntingt) 1998;11(8 Suppl 8):46-9.
95. Carmichael J, Hegg R, Firat D, Pawlicki M, Le Bras F, Delgado FM, et al. Navelbine (NVB) and fractionated dose doxorubicin (DX) improves first line advanced breast cancer (ABC): An overview of 3 Phase II trials. Br J Cancer 1997;76 Suppl 1:44.
96. Conti F, Vici P. Vinorelbine in the treatment of breast cancer: Current status and prospectives for the future. Clin Ter 1998;149:61-74.
97. Fumoleau P, Delozier T, Monnier A, Garcia-Conde J, Lluch A, Diaz Rubio E, et al. Navelbine (NVB) single agent as first line chemotherapy in disseminated breast carcinoma: Results of two European multicenter Phase II trials. Anticancer Res 1992;12:1794.
98. Hochster H. Vinorelbine therapy in previously treated patients with metastatic breast cancer. Can J Inf Dis 1995;6 Suppl C:262c.
99. Spielmann M, Jouve M, Turpin F, Dieras V, Extra JM, Marty M, et al. Navelbine (NVB) combination chemotherapies in advanced breast cancer (ABC) as a first line treatment: NVB-fluorouracil and NVB-doxorubicin as promising new regimens: Report of two Phase II trials. Anticancer Res 1992;12:1904.
100. Mobus V. Experiences with Caelyx registered in the treatment of metastatic breast cancer. Onkologie 2000;23 Suppl 2:20-5.
101. Adenis A, Vanlemmens L, Fournier C, Hecquet B, Bonneterre J. Does induction chemotherapy with a mitoxantrone/vinorelbine regimen allow a breast-conservative treatment in patients with operable locoregional breast cancer? A French Northern Oncology Group trial in 105 patients. Breast Cancer Res Treat 1996;40:161-9.
102. Agostara B, Gebbia V, Testa A, Cusimano MP, Gebbia N, Callari AM. Mitomycin "C" and vinorelbine as second line chemotherapy for metastatic breast carcinoma. Tumori 1994;80:33-6.
103. Azim HA. Treatment of metastatic breast cancer by Navelbine, mitoxantrone and continuous infusion 5-fluorouracil (FMN regimen): Results of a pilot study. J Infus Chemother 1996;6:102-6.
104. Aziz Z, Rehman A, Qazi S. Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy. Cancer Chemother Pharmacol 1999;44:S9-12.
105. Baldini E, Tibaldi C, Da Prato M, Chiavacci A, Di Lieto M, Taviani R, et al. Epirubicin (EPI) + Navelbine (NVB) as first line chemotherapy in advanced breast cancer (ABC) patients (PTS): A multicentric Phase II study. Eur J Cancer 1996;32A Suppl 1:S17.
106. Barni S, Ardizzoia A, Bernardo G, Villa S, Strada MR, Cazzinaga M, et al. Vinorelbine as single agent in pretreated patients with advanced breast cancer. Tumori 1994;80:280-2.
107. Blomqvist C, Hietanen P, Teerenhovi L, Rissanen P. Vinorelbine and epirubicin in metastatic breast cancer: A dose finding study. Eur J Cancer 1995;31:2406-8.
108. Borquez D, Harstrick A,Klaasen U, Beling C, Mayer S, Seeber S. Final results of a Phase I/II study of vinorelbine, high-dose folinic acid and infusional 5-FU in patients with anthracycline or taxane pretreated metastatic breast cancer. Breast Cancer Res Treat 1999;57:87.
109. Braud AC, Jauffret E, Kirova YM, Piedbois P, Levy E. Phase II study of neoadjuvant chemotherapy combining epirubicin cyclophosphamide and vinorelbine (NEC) in locally advanced breast cancer (LABC): Preliminary results. Eur J Cancer 1999;35 Suppl 4:S206.
110. Brockstein B, Mauer A, Masters G, Hoffman PC, Skoog LA, Bitran JD, et al. A Phase II study of ifosfamide and Navelbine for advanced breast cancer. Breast Cancer Res Treat 1996;41:236.
111. Budman DR, Weiselberg L, O'Mara V. Re: Severe neurotoxicity in vinorelbine-paclitaxel combinations. J Natl Cancer Inst 1997;89:87-8.
112. Buonadonna A, Crivellari D, Frustaci S, Stefanovski PD, Sorio R, Veronesi A, et al. Vinorelbine (VRL) as palliative treatment in elderly patients (PTS) with metastatic breast cancer. Breast Cancer Res Treat 1997;46:96.
113. Burstein HJ, Kuter I, Richardson PG, Campos SM, Parker L.M, Matulonis UA, et al. Herceptin (H) and vinorelbine (V) as second-line therapy for HER-2-positive (HER2+) metastatic breast cancer (MBC): A Phase II study. Breast Cancer Res Treat 1997;57:29.
114. Campisi C, Fabi A, Papaldo P, Tomao S, Massidda B, Zappala A, et al. Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: A Phase I-II clinical trial. Cancer Chemother Pharmacol 1999;44 Suppl:S1-4.
115. Canobbio L, Boccardo F, Pastorino G, Brema F, Martini C, Resasco M, et al. Phase II study of Navelbine in advanced breast cancer. Semin Oncol 1989;16(2 Suppl 4):33-6.
116. Cardamakis E, Ginopoulos P. Navelbine in the treatment of breast cancer. Anticancer Res 1998;18:3828.
117. Chang A, Garrow G, Hines J. Pilot study of vinorelbine (V, Navelbine) and paclitaxel (P, Taxol) in patients with refractory breast cancer. Breast Cancer Res Treat 1996;37 Suppl:91.
118. Chang AY, Rubins J. Phase I/II study of gemcitabine, Navelbine, and cisplatin in advanced breast cancer and non-small-cell lung cancer. Cancer Invest 1999;17 Suppl 1:42-3.
119. Chollet P, Charrier S, Cure H, Brain E, Van Praagh I, Feillel V, et al. Neoadjuvant chemotherapy in operable breast cancer: High pathological response rate induced by vinorelbine-anthracycline-based regimen. Breast Cancer Res Treat 1997;46:74.
120. Cocconi G, Mambrini A, Quarta M, Visini G, Bella MA, Ferrozzi F, et al. Vinorelbine combined with paclitaxel infused over 96 hours (VI-TA-96) for patients with metastatic breast carcinoma. Cancer 2000;88:2731-8.
121. Cole JT, Gralla RJ, Kardinal CG. Navelbine and mitomycin C: Combination therapy in advanced breast cancer. Breast Cancer Res Treat 1994;32 Suppl.33.
122. Dieras V, Varette C, Louvet C, Espie M, Colin P, Marty M. Navelbine-5-fluorouracil combination in 1st line treatment of advanced breast-cancer. In: Navelbine (Vinorelbine): Update and New Trade. Montrouge: John Libbey Eurotext Ltd; 1991. p. 221-7.
123. Extra JM, Leandri S, Dieras V, Ferme C, Mignot L, Morvan F, et al. Phase-II study of vinorelbine in 1st and 2nd line treatment of advanced breast-cancer. In: Navelbine (Vinorelbine): Update and New Trade. MOntrouge: John Libbey Eurotext Ltd; 1991. p. 213-20.
124. Fabi A, Tonachella R, Savarese A, Cirulli S, Tomao S, Conte E, et al. A Phase II trial of vinorelbine and thiotepa in metastatic breast cancer. Ann Oncol 1995;6:187-9.
125. Ferrari VD, Marpicati P, Montini E, Rangoni G, Simoncini E, Marinl G. Vinorelbine (VNB) plus raltritexed in advanced breast cancer (ABC), a Phase II study: Preliminary results. Eur J Cancer 1999;35 Suppl 4:S328.
126. Froudarakis ME, Catimel G, Guastalla JP, Rebattu P, Clavel M. Phase II trial of navelbine and fluorouracil as second-line chemotherapy in metastatic breast carcinoma. Oncology 1998;55:87-8.
127. Gaafar RM, Hamza MR, El Zawahry H, Khaled H, Helal A, Eissa S, et al. Vinorelbine and farmorubicin as neoadjuvant chemotherapy in locally advanced breast cancer. Eur J Cancer 1999;35 Suppl 4:S329.
128. Galvez C, Bonamassa MM, Ares S. A Phase II trial of the use of docetaxel (D): Vinorelbine (VNB) in combination with GM-CSF in taxol refractory metastatic breast cancer (MBC). Breast Cancer Res Treat 1997;46:95.
129. Garcia-Conde J, Lluch A, Casado A, Martin M, Diaz-Rubio E, Oliveira C, et al. Phase II trial with navelbine (NVB) in advanced breast cancer (ABC) previously untreated. Breast Cancer Res Treat 1992;23:143.
130. Gomez-Bernal A, Cruz JJ, Garcia Palomo A, Arizcun A, Pumol E, Diz P, et al. Docetaxel and vinorelbine in patients with metastatic breast cancer after using anthracyclines. Breast Cancer Res Treat 1999;57:87.
131. Gralow JR, Ellis GK, Williams MA, Livingston RB. Docetaxel + vinorelbine with concurrent G-CSF support: A Phase II study in stage IV breast cancer. Breast Cancer Res Treat 1999;57:88.
132. Hegg R, Correa M, Yamaguchi N, Novaes NMV, Andrade CA, Agnelli A, et al. Naveline (NVB) 25mg/m-2 and doxorubicin (DX) 25mg/m-2, on day 1 and 8 for the treatment of metastatic breast cancer. Breast Cancer Res Treat 1996;41:287.
133. Hochster H, Vogel C, Blumenreich M, Brown JG, Davis H, Graham M, et al. A US multicenter Phase II study of navelbine (NVB) and doxorubicin (DOX) as first line chemotherapy of metastatic breast cancer. Breast Cancer Res Treat 1994; 32 Suppl:93.
134. Kornek GV, Haider K, Kwasmy W, Depisch D, Kovats E, Lang FC, et al. Treatment of advanced breast cancer with vinorelbine (VLB), fluorouracil (FU), L-leucovorin (LLV), and human granulocyte colony-stimulating factor (GCSF). Ann Hematol 1996;73 Suppl 2:A70.
135. Kornek G, Haider K, Kwasny W, Ulrich-Pur H, Raderer M, Hejna M, et al. Treatment of advanced breast cancer with taxotere and vinorelbine (VLB) +/- human granulocyte colony-stimulating factor (GCSF). Eur J Cancer 1999;35 Suppl 4:S321.
136. Martin JP, Dieras V, Berdeaux G. Epidemiology and economics of chemotherapy combinations in the treatment of advanced breast cancer. Therapie 2000;55:127-31.
137. Martin M, Garcia Carbonero I, Casado A, Oruezabal M, Macias JA, Garcia Saenz JA, et al. Weekly taxol plus navelbine in metastatic breast cancer patients (MBCP) with prior doxorubicin treatment. Breast Cancer Res Treat 1999;57:90.
138. Masters G, Heimann R, Skoog L, Posner M, Shulman K, Malone D, et al. Concomitant chemoradiotherapy with vinorelbine (VNB) and paclitaxel (TAX) with filgrastim (G-CSF) support in patients (pts) with unresectable breast cancer. Breast Cancer Res Treat 1997;46:75.
139. Mlineritsch B, Hausmaninger H, Maca M, Oman J, Mayer P, Rass C. Vinorelbine and 5-fluorouracil in the treatment of advanced breast cancer. Ann Hematol 1996;73 Suppl 2:A69.
140. Mustacchi G, Milani S, Sandri P, Piuca E, Muggia M, Carbonara T, et al. Cisplatin (CP)-vinorelbine (VNB): A new active combination in metastatic breast cancer. Breast Cancer Res Treat 1994;32 Suppl:36.
141. Nistico C, Pace A, Ranuzzi M, Bove L, Mottolese M, Caruso A, et al. Systemic and neurological toxicity of combined treatment epirubicin (EPI) plus vinorelbine (VNR) in advanced breast cancer (ABC): Preliminary results [meeting abstract]. Proceedings of the 86th Annual Meeting of the American Association for Cancer Research; 1995 Mar 18-22; Toronto, Canada. Philadelphia, PA: AACR; 1995. p. 367.
142. Pawlicki M, Siedlecki P, Zaluski J, Ramlau C, Rolski J, Burillon JP, et al. A multicenter Phase II study of navelbine (NVB) and doxorubicin (DOX) as
143. Pienkowski T, Gruszfeld A, Bauer B. Vinorelbine and five-days continuous infusion of 5-fluorouracil in pretreated breast cancer patients. Breast Cancer Res Treat 1999;57:86.
144. Pronzato P, Gardin G, Tognoni A, Vigani A, Vaira F, Gasco M. Vinorelbine and paclitaxel in advanced breast cancer. Eur J Cancer 1999;35 Suppl 4:S321.
145. Pronzato P, Queirolo P, Vecchio S, Landucci M, Vaira F, Vigani A. Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer. Breast Cancer Res Treat 1996;41:287.
146. Rodriguez R, Cuevas JM, Machens I, Ruiz M, Espinosa E, Dorta J, et al. Docetaxel-vinorelbine as second line chemotherapy for advanced breast carcinoma. Breast Cancer Res Treat 1999;57:85.
147. Rueger I, Schroeder M, Westerhausen M. Navelbine, 5-fluorouracil/calciumfolinat and adriamycin in pretreated patients with progressive metastatic breast cancer. Onkologie 1995;18 Suppl 2:101.
148. Scheithauer W, Haider K, Kwasny W, Kornek G, Raderer M, Tueni C, et al. Effective chemotherapy for advanced breast cancer with high-dose vinorelbine, mitomycin-C and recombinant human granulocyte colony-stimulating factor. In: Kubista E, Staffen A, Zielinski C, editors. Proceedings of the 2nd European Congress on Senology; 1994 Oct 2-6; Vienna, Austria. Bologna, Italy: Monduzzi Editore; 1994. p. 171-3.
149. Taylor CW, Alberts DS. A clinical trial of intravenous navelbine plus high dose tamoxifen in patients with advanced breast cancer. Breast Cancer Res Treat 1996;41:285.
150. Zambetti M, Demicheli R, De Candis D, Antonelli G, Giacobone A, Terenziani M, et al. Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients. Breast Cancer Res Treat 1997;44:255-60.
151. Morere JF, Boaziz C, Coulon MA, Bouillet T, Hennebelle F, Kanoui A, et al. Clinical Phase II study of paclitaxel (P) combined with vinorelbine (V) in metastatic breast cancer. Proceedings of the 90th Annual Meeting of the American Association for Cancer Research; 1999 Apr 10-14; Philadelphia, PA, USA. Philadelphia, PA: AACR; 1999. p. 496.
152. Kornek GV, Haider K, Kwasny W, Hejna M, Raderer M, Schenk T, et al. Treatment of advanced breast cancer with vinorelbine (VLB), fluorouracil (FU), L-leucovorin (LLV), and human granulocyte colony-stimulating factor (GCSF). Eur J Cancer 1996;32A Suppl 1:S20.
153. Bergeron A, Raffy O, Vannetzel JM, Pinedo HM, Van Groeningen CJ. Myocardial ischemia and infarction associated with vinorelbine. J Clin Oncol 1995;13:531-2.
154. De Matteis A, Nuzzo F, Rossi E, Landi G, Perrone F. Intestinal side-effects of docetaxel/vinorelbine combination. Lancet 2000;355:1098-9.
155. Colleoni M, Manente P, Stocker J, Amor H, Lamon S, Nelli P, et al. A randomized Phase II trial of two different schedules of mitomycin C and vinorelbine in pretreated breast cancer. Oncology 1997;54:438-9.
156. Coudert B. Randomized study of vinorelbine combined with chronomodulated fluorouracil in previously treated women with metastatic breast cancer. In: PDQ [monograph online]. Bethesda: National Cancer Institute; 1999. URL: http://cancernet.nci.nih.gov/trialsrch.shtml
157. Lozano M, Arrieta J, Polera J, Uranga G, Bonicatto S, Ferro A, et al. Navelbine (NVB) plus mitomycin (MMC) or mitoxantrone (MTZ) as salvage regimen in metastatic breast cancer (MBC): A randomized trial. Eur J Cancer 1997; 33 Suppl 8:S153-4.
158. Hillner BE. Role of decision analysis in relation to clinical trials and a US perspective of the Battelle model. Pharmacoeconomics 1996;9 Suppl 2:30-6.
159. Hutton J, Brown RE, Borowitz M, Abrams K, Rothman M, Shakespeare A. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 1996;9 Suppl 2:8-22.
160. Spielmann M. Navelbine in combination with anthracycline or anthracenedione. Bull Soc Fr Cancerol Priv 1996;15:49-51.
161. Barth J. Vinorelbine monography. Krankenhauspharmazie 1999;20:97-8.
162. Anderson L, Cox J. A systematic review of docetaxel, paclitaxel and vinorelbine in the treatment of advanced breast cancer in the UK. Br J Cancer 2000;83 Suppl 1:49.
163. Bordeaux G, Hurteloup P, Launois R, Reboul Marty J, Henry B, Bonneterre J. Cost utility in second-line metastatic breast cancer. Pharmacoeconomics 1997;11:492-7.
164. Cure H, Charrier S, Ferriere JP, Van Praagh I, Assier I, Feillel V, et al. Results of 3 neoadjuvant chemotherapy regimens for operable breast cancer. Bull Cancer 1997;84:31-4.
165. Bertsch LA, Donaldson G. Quality of life analyses from vinorelbine (Navelbine) clinical trials of women with metastatic breast cancer. Semin Oncol 1995;(2 Suppl 5):45-53.
166. Venturino A, Simoni C, Granetto C, Pronzato P, Porcile GF, Fusco V, et al. Randomized Phase II trial with Navelbine (NVB) vs mitoxantrone+5-FU+L-LV (MFL), vs 5-FU+L-LV (FL) in 72 patients with refractory metastatic breast cancer. Breast Cancer Res Treat 1996;41:235.
167. Simoni C, Venturino A, Pronzato P, Procile GF, Fusco V, Merlini L, et al. Multicenter randomized Phase II clinical trial with Navelbine (NVB) vs mitoxantrone+5-FU+L-LV (MFL), vs 5-FU+L-LV (FL) in 64 patients with refractory metastatic breast cancer. Anticancer Res 1995;15:1772-3.
168. Blajman C, Balbiani L, Block J, Bianchi R, Temperley G, Chacon R, et al. Navelbine (N) plus adriamycin (A) vs FAC in advanced breast cancer (ABC) [meeting abstract]. Proceedings of the 29th Annual Meeting of the American Society of Clinical Oncology; 1993 May 16-18; Orlando, FL, USA. Alexandria, VA: ASCO; 1993. A170.
169. Blajman C, Balbiani L, Coppola F, Bader M, Fein L, Bonicatto S. Phase III study: Navelbine (N) plus adriamycin (A) versus fluorouracil (F) plus A plus cyclophosphamide (C) in advanced breast cancer (ABC). Ann Oncol 1996;7 Suppl 5:26.
170. Norris B, Pritchard K, James K, Myles J, Bennett K, Marlin S, et al. A Phase III comparative study of vinorelbine (VNB) combined with doxorubicin (DOX) versus doxorubicin alone in metastatic/recurrent breast cancer (MBC): A National Cancer Institute of Canada (NCIC CTG) study [meeting abstract]. Proceedings of the 32nd Annual Meeting of the American Society of Clinical Oncology; 1996 May 18-21; Philadelphia, PA, USA. Alexandria, VA: ASCO; 1996. A59.
171. Norris B, Pritchard K, James K, Myles J, Bennett K, Marlin S, et al. A Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer. Clin Invest Med 1996;19 Suppl 4:S61.
172. Frasci G, Comella P, Apicella A, D'Aiuto G, Thomas R, Capasso I, et al. Weekly docetaxel (D) plus gemcitabine (G) or vinorelbine (V) in refractory advanced breast cancer (ABC) patients: A parallel dose-finding study. Eur J Cancer 1999;35 Suppl 4:S325.
173. Bonneterre J, Roche H, Monnier A, Serin D, Fargeot P, Guastala JP, et al. Taxotere (TXT) versus 5-fluorouracil + Navelbine (FUN) as second-line chemotherapy (CT) in patients (pts) with metastatic breast cancer (MBC) (preliminary results) [meeting abstract]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology; 1997 May 17-20; Denver, CO, USA. Alexandria, VA: ASCO; 1997. A564.
174. Namer M, Turpin F, Serin D, Ganem G, Calasi G, Maillart P, et al. Prospective randomized study of mitoxantrone (M) and vinorelbine (V) vs FAC or FEC in ABC. Br J Cancer 1998;78 Suppl 2:25.
175. Namer M, Soler-Michel P, Mefti F, Creisson C, Chinet-Charrot P, De Gislain C, et al. Is the combination FAC/FEC always the best regimen in advanced breast cancer (ABC)? Utility of mitoxantrone (M) and vinorelbine (V) association as an alternative in some situations: Results from a Phase III prospective randomized trial. Breast Cancer Res Treat 1997;46:94.
176. Namer M, Soler Michel P, Turpin F, Chinet Charro P, De Gislain C, Pouillart P, et al. Prospective randomized study comparing mitoxantrone (M) and vinorelbine (V) with fluorouracil (F), epirubicin (E) or adriamycin (A) and cyclophosphamide (C) in patients with metastatic breast cancer [meeting abstract]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology; 1997 May 17-20; Denver, CO, USA. Alexandria, VA: ASCO; 1997. A520.
177. Khan KS, Ter Riet G, Glanville J, Sowdon AJ, Kleijnen J. Undertaking Systematic Reviews of Research on Effectiveness: CRD's Guidance for Carrying out or Commissioning Reviews. 2nd ed. York: NHS Centre for Reviews and Dissemination; 2001. Report No.: CRD Report 4.
178. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: The importance of rigorous methods. BMJ 1996;313:36-9.
179. Nistico C, Pace A, Ranuzzi M, Bove L, Mottolese M, Caruso A, et al. Systemic and neurological toxicity of combined treatment epirubicin (EPI) + vinorelbine (VNR) in advanced breast cancer (ABC): Preliminary results [meeting abstract]. Proceedings of the 86th Annual Meeting of the American Association for Cancer Research; 1995 Mar 18-22; Toronto, Ontario, Canada. Philadelphia, PA: AACR; 1995. A2187.
180. Thall PF, Simon RM. Recent developments in the design of Phase II clinical trials. In: Thall PF, editor. Recent Advances in Clinical Trial Design and Analysis. Boston: Kluwer Academic; 1995. p. 49-71.
181. Gallbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med 1988;7:889-94.
182. Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Horner D, et al. Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994;5:423-6.
183. Cameron A. Advanced breast cancer: A NICE result for docetaxel. Pharmacoeconomics & Outcomes News 2000;49:3-4.
184. Ball C, Sackett D, Phillips B, Haynes B, Straus S. Levels of evidence and grades of recommendations [monograph online]. Oxford: Centre for Evidence-Based Medicine; 1999. [cited 2001 Jan 26]. URL: http://cebm.jr2.ox.ac.uk/docs/levels.html
185. Schultz K, Chalmers I, Hayes R, Altman D. Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
186. Ernst E, White A. Acupuncture for back pain: A meta-analysis of randomised controlled trials. Arch Int Med 1998;158:2235-41.
187. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34.
188. Byar DP, Schoenfeld DA, Green SB, Amato DA, Davis R, De Gruttola V, et al. Design considerations for AIDS trials. N Engl J Med 1990;323:1343-8.
189. Launois RJ, Reboul Marty JM, Bonneterre J. A medico-economic evaluation of second line chemotherapy in metastatic breast cancer: Comparison between docetaxel, paclitaxel, and vinorelbine. Bull Cancer 1997;84:709-21.
190. Chica Marchal AM, Lopez Carretero E, Acosta Robels PJ, Gonzalez Romero J, Tarin Remohi MJ, Ortega Jimenez JM. Pharmacoeconomic study of intravenous antineoplastic therapy in a centralized cytostatics unit. Farm Clin 1995;12:202-9.
191. Egger M, Zellweger-Zahner T, Schneider M, Junker C, Lengeler C, Antes G. Language bias in randomised controlled trials published in English and German. Lancet 1997;350:326-9.
192. Williams C. Cancer Biology and Management: An Introduction. Chichester: Wiley, 1990.
193. Bercez C, Viens G, Bonneterre ME, Bonneterr J. An approach of the evaluation of costs induced by clinical research: The experience of a French Oncology department [meeting abstract]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology; 1997 May 17-20; Denver, CO, USA. Alexandria, VA: ASCO; 1997. A1481.
194. Budman DR. Vinorelbine (Navelbine): A third-generation vinca alkaloid. Cancer Invest 1997;15:475-90.
195. Schubert FR. Pharmacoeconomic aspects of breast cancer treatment: Presentation of a computer model [meeting abstract]. Can J Inf Dis 1995; 6 Suppl C:262c.
196. Abrahamova J, Wagnerova M, Kubala E, Malec V, Simova E, Sirakova I, et al. Navelbine + epirubicin + methotrexate (NEM) as neoadjuvant treatment for locally advanced breast carcinoma (LABC) [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 15-18; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A477.
197. Adams DJ. Synergy of Navelbine-Taxol combination treatment in two human breast cancer cell lines [meeting abstract]. Proceedings of the 85th Annual Meeting of the American Association for Cancer Research; 1994 Apr 10-13; San Francisco, CA, USA. Philadelphia, PA: AACR; 1994. p. 327.
198. Adams DJ, Knick VC. MDR and non-MDR forms of cellular resistance to 5′ noranhydrovinblastine Navelbine. Proceedings of the 83rd Annual Meeting of the American Association for Cancer Research; 1992 May 20-23; San Diego, CA, USA. Philadelphia, PA: AACR; 1992. p. 462.
199. Adenis A, Vanlemmens L, Fournier C, Hecquet B, Bonneterre J. Mitoxantrone (DHAD) and vinorelbine (VNR) as a primary treatment of locoregional breast cancer (BC) [meeting abstract]. Proceedings of the 86th Annual Meeting of the American Association for Cancer Research; 1995 Mar 18-22; Toronto, Canada. Philadelphia, PA: AACR; 1995. A253.
200. The efficacy and tolerance of Navelbine in the treatment of breast cancer metastases. Concours Med 1991;113:1508.
201. Vinorelbine/paclitaxel combination studied in treatment of metastatic breast cancer patients. Oncology (Huntingt) 1995;9:518, 543.
202. Ibrahim N, Hortobagyi GN, Valero V, Dhingra K, Willey J, Hohneker J, et al. Phase I study of vinorelbine (NVB; Navelbine) and paclitaxel (PTX) by simultaneous (sim) 3-hr infusion (inf) for untreated metastatic breast cancer (MBC) [meeting abstract]. Proceedings of the 86th Annual Meeting of the American Association for Cancer Research; 1995 Mar 18-22; Toronto, Canada. Philadelphia, PA: AACR; 1995. A1443.
203. Navelbine in the treatment of bronchial and breast carcinoma. Onkologie 1996;2:196-7.
204. Oral vinorelbine promising and well tolerated in patients with advanced breast cancer. Oncology (Huntingt) 1997;11:255.
205. Ardavanis A, Pissakas G, Missitzis I, Armonis B, Pateras C, Bousboukea A, et al. Multidisciplinary therapy of locally advanced breast cancer (LABC) with an induction chemotherapy combination of fluorouracil, epirubicin and vinorelbine (FEN) followed by surgery and postoperative chemoradiotherapy: An ongoing Phase II study [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 15-18; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A485.
206. Barni S, Ionta MT, Battelli T, Ardizzoia A, Schieppati G, Frontini L, et al. L-PEV: A very challenging and active chemotherapy regimen in locally advanced breast cancer (LABC) [meeting abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta, GA, USA. Alexandria, VA: ASCO; 1999. A331.
207. Bash-Babula JE, Alli E, Hait WN, Toppmeyer D. A Phase I/II clinical trial of doxorubicin and vinorelbine: Effects on p53 and microtubule-associated protein 4 (MAP4) expression in patients with advanced breast cancer [meeting abstract]. Proceedings of the 92nd Annual Meeting of the American Association for Cancer Research; 2001 Mar 24-28; New Orleans, LA, USA. Philadelphia, PA: AACR; 2001. p. 119.
208. Besenval M, Delgado M, Demarez JP, Krikorian A. Safety and tolerance of Navelbine in Phase I-II clinical studies. Semin Oncol 1989;16(2 Suppl 4):37-40.
209. Botto HG, Botto ME, Otegui ML, Delia R. Taxotere (TXT) vs vinorelbine and Taxol (VIN-TAX) in patients (PTS) with metastatic breast cancer (MBC) anthracycline resistants [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 15-18; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A498.
210. Bowen K, Burris H, Rodriguez G, Shaffer D, Fields S, Bigley J, et al. A Phase I trial of chronic oral Navelbine administration [meeting abstract]. Proceedings of the 83rd Annual Meeting of the American Association for Cancer Research; 1992 May 20-23; San Diego, CA, USA. Philadelphia, PA: AACR; 1992. p. 519.
211. Budman DR, Weiselberg L, O'Mara V, Buchbinder A, Lichtman SM, Donahue L, et al. A Phase I study of sequential vinorelbine followed by paclitaxel. Ann Oncol 1999;10:861-3.
212. Burris HA, III, Hainsworth JD, Greco FA. Combination therapy with weekly schedules of docetaxel, gemcitabine, and vinorelbine. Cancer Invest 2000;18 Suppl 1:89-91.
213. Burstein HJ, Ramirez MJ, Petros WP, Clarke KD, Warmuth MA, Marcom PK, et al. Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol 1999;10:1113-16.
214. Cannizzaro R, Robieux I, Sorio R, Borsatti E, Freschi A, Tumolo S, et al. Correlation between the quantitative liver function test "MEGX" and vinorelbine clearance in patients with breast cancer [meeting abstract]. Proceedings of the 95th Annual Meeting of the American Gastroenterological Association and Digestive Disease Week; 1995 May 14-17; San Diego, CA, USA. Bethesda, MD: American Gastroenterological Association, A1044.
215. Cany L, Toulouse C, Ravaud A, Durand M, Mauriac L. Vinorelbine/5-FU combination in metastatic breast cancer chemotherapy: A retrospective study of 63 cases. Eur J Cancer 1996;32a:370-1.
216. Cattan CE, Oberg KC. Vinorelbine tartrate-induced pulmonary edema confirmed on rechallenge. Pharmacotherapy 1999;19:992-4.
217. Chadjaa M, Izzo J, Levin FM, Riggi M, Armand JP, Cvitkovic E. Preliminary data on 4′ epiadriamycin (EPI) plus vinorelbine (VNB) a new active combination in advanced breast cancer (ABC). Proceedings of the 83rd Annual Meeting of the American Association for Cancer Research; 1992 May 20-23; San Diego, CA, USA. Philadelphia, PA: AACR; 1992. p. 214.
218. Chang AY, Garrow GC. Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer. Semin Oncol 1995;22(2 Suppl 5):66-71.
219. Charrier S, Communal Y, Cure H, Chollet P, Portefaix G, Ferriere JP, et al. Mobilization of peripheral blood stem cells (PBSC) after primary intense chemotherapy and granulocyte-colony stimulating factor (G-CSF) in breast cancer [meeting abstract]. Proceedings of the 83rd Annual Meeting of the American Association for Cancer Research; 1992 May 20-23; San Diego, CA, USA. Philadelphia, PA: AACR; 1997. p. A168.
220. Charrier S, Van Praagh I, Cure H, Achard JL, Ferriere JP, Feillel V, et al. Ovarian function preservation following VEM (vinorelbine, epirubicine and methotrexate) neo- or adjuvant chemotherapy in 49 breast cancers. Breast Cancer Res Treat 1997;46:96.
221. Charrier S, Chassagne J, Cure H, Bay JO, Communal Y, Portefaix G, et al. Mobilization of peripheral blood progenitor cells after induction chemotherapy (THP-doxorubicin-vinorelbine-cyclophosphamide-fluorouracil) and granulocyte colony-stimulating factor in breast cancer. Bone Marrow Transplant 1998;22:845-51.
222. Charrier S, Chollet P, Bay JO, Cure H, Kwiatkowski F, Portefaix G, et al. Hematological recovery and peripheral blood progenitor cell mobilization after induction chemotherapy and GM-CSF plus G-CSF in breast cancer. Bone Marrow Transplant 2000;25:705-10.
223. Charrier S, Portefaix G, Chollet P, Kwiatkowski F, Communal Y, Cure H, et al. Red blood cells (RBC) and high fluorescence reticulocytes (HFR) production increased by induction chemotherapy and GM-CSF plus G-CSF in peripheral blood of breast cancer patients. Hematol Cell Ther 2000;42:165-70.
224. Chevallier B, Bonnetterre J, Le Bras F, Focan C, Mauriac L, Piccart M, et al. Phase I clinical trial of oral vinorelbine (VRL) in patients (PTS) with advanced breast cancer (ABC): Preliminary results [meeting abstract]. Proceedings of the 9th Annual San Antonio Breast Cancer Symposium on Breast Cancer Research and Treatment; 1996 Dec 11-14; San Antonio, TX, USA. 1997, p. 286.
225. Chollet P, Charrier S, Cure H, Brain E, Van Praagh I, Feillel V, et al. Neoadjuvant chemotherapy in operable breast cancer. High pathological response rate induced by vinorelbine-anthracycline-based regimen [meeting abstrac]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology; 1997 May 17-20; Denver, CO, USA. Alexandria, VA: ASCO; 1997. A573.
226. Chollet P, Charrier S, Brain E, Cure H, Van Praagh I, Feillel V, et al. Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 1997;33:862-6.
227. Cohen RB, Mueller SC, Haden K, De Souza P. Phase I study of weekly vinorelbine in combination with weekly paclitaxel in adult patients with advanced refractory cancer. Cancer Invest 2000;18:422-8.
228. Colleoni M, Gaion F, Vicario G, Nelli P, Pancheri F, Sgarbossa G, et al. Pain at tumor site after vinorelbine injection: Description of an unexpected side effect. Tumori 1995;81:194-6.
229. Colleoni M, Vicario G, Graiff C, Pancheri F, Sgarbossa G, Nelli P, et al. Treatment of brain metastases from breast and lung adenocarcinoma with CCNU, vinorelbine, carboplatin and fluorouracil plus folates [meeting abstract]. Proceedings of the 6th International Congress on Anti-Cancer Treatment; 1996 Feb 6-9; Paris, France. Paris: Service d'Oncologie Medicale Pitie-Salpetriere; 1996. p. 110.
230. Colleoni M, Graiff C, Nelli P, Vicario G, Sgarbossa G, Pancheri F, et al. Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma. Am J Clin Oncol 1997;20:303-7.
231. Colleoni M, Manente P, Stocker J, Amor H, Lamon S, Nelli P, et al. Mitomycin C and vinorelbine in pretreated breast cancer. Tumori 1997;83:834-6.
232. Colleoni M, Minchella I, Orvieto E, Peruzzotti G, Nole F, Viale G, et al. Prediction of response to primary chemotherapy (PCT) for operable breast cancer. Presentation at the Third Education Convention of the European School of Oncology; 1998 May 20; Turin, Italy.
233. Colleoni M, Orlando L, Robertson C, Nole F, Peruzzotti G, Cassano R, et al. Assessment of response in primary chemotherapy for breast cancer. Ann Oncol 1998;9:1140-1.
234. Colleoni M, Orvieto E, Nole F, Orlando L, Minchella I, Viale G, et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur J Cancer 1999;35:574-9.
235. Colleoni M, Minchella I, Mazzarol G, Nole F, Peruzzotti G, Rocca A, et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 2000;11:1057-9.
236. Craig JB, Jones SE, Dillman RO, Hohneker J, Smalley RV. Vinorelbine (navelbine) and doxorubicin (adriamycin) (NA) in combination for advanced breast cancer - Phase 1 evaluation of a new schedule. Breast Cancer Res Treat 1993;27:145.
237. Crivellari D, Magri MD, Buonadonna A, Cicco MD, Ferlante MA, Paolello C, et al. Palliative treatment with 5-fluorouracil (FU) continuous infusion (CI) [plusmn] navelbine (NVB) in metastatic, anthracycline refractory breast cancer [meeting abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta, GA, USA. Alexandria, VA: ASCO; 1999. A436.
238. Culine S, Roch I, Pinguet F. Combination paclitaxel and vinorelbine therapy: In vitro cytotoxic interactions and dose-escalation study in patients with anthracycline-resistant metastatic breast cancer [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 15-18; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A515.
239. Culine S, Roch I, Pinguet F, Romieu G, Bressolle F. Combination paclitaxel and vinorelbine therapy: In vitro cytotoxic interactions and dose-escalation study in breast cancer patients previously exposed to anthracyclines. Int J Oncol 1999;14:999-1006.
240. Daldoul O, Mezlini A, Khalfallah S, Rais H, Ben Ayed F. Vinorelbine (VNB) and cisplatin (CDDP) in metastatic breast cancer (MBC) after failure of anthracycline-containing regimens [meeting abstract]. Proceedings of the 9th International Congress on Anti-Cancer Chemotherapy; 1999 Feb 2-5; Paris, France. Paris: Service d'Oncologie Medicale Pitie-Salpetriere; 1999. p. 199.
241. De Boer R. Gemcitabine and vinorelbine in advanced breast cancer. Breast Cancer Res 2002;2:368.
242. De Braud F, Nole F, De Pas T, Aapro MS. Extrapyramidal like reaction post high-dose navelbine: An unreported severe side effect [meeting abstract]. Proceedings of the 86th Annual Meeting of the American Association for Cancer Research; 1995 Mar 18-22; Toronto, Canada. Philadelphia, PA: AACR; 1995. A1427.
243. Delecroix V, Fumoleau P, Perrocheau G, Azli N, Fety R, Priou F, et al. Anthracycline as second-line chemotherapy (CT) for metastatic breast cancer patients previously treated with taxotere (TXT) [meeting abstract]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology; 1997 May 17-20; Denver, CO, USA. Alexandria, VA: ASCO; 1997. A578.
244. Deplanque G, Duclos B, Limacher JM, Eichler F, Essner G, Dufour P, et al. Doxorubicin, docetaxel and vinorelbine (ATN) with G-CSF support in the treatment of metastatic breast cancer (MBC): A pilot study [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 15-18; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A525.
245. Dittrich C, Zifko U, Fazeny B, Fiegl M, Grisold W, Huber H. Vinorelbine after paclitaxel in breast cancer: Cross resistance and cumulative neurotoxicity? Ann Oncol 1994;5:473-4.
246. Ellis PA, Smith IE. Primary chemotherapy for early breast cancer. Cancer Treat Rev 1996;22:437-50.
247. Ellis GK, Gralow JR, Pierce HI, Williams MA, Livingston RB. Paclitaxel/vinorelbine (TV) chemotherapy with concurrent G-CSF for metastatic breast cancer (MBC): Phase I-II study in doxorubicin-treated patients (PTS) [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 15-18; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A528.
248. Ellis GK, Gralow JR, Pierce HI, Williams MA, Livingston RB. Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: High complete response rate in a Phase I-II study of doxorubicin-treated patients. J Clin Oncol 1999;17:1407-12.
249. Escudero P, Bueso P, Mayordomo JI, Isla D, Cajal R, Yubero A, et al. Docetaxel + vinorelbine is an active combination for patients with anthracycline-refractory metastatic breast cancer: Results of a Phase II trial [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 15-18; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A529.
250. Ferrero JM, Namer M, Dufour JF, Largiller R, Creisson A, Teissier E, et al. A comparative study of 4 sequential first-line chemotherapy protocols in locally advanced breast cancer. Bull Cancer 1997;84:10-16.
251. Ferrero JM, Namer M, Romaioli A, Lallement M, Macchiavello JC, Teissier E, et al. Neoadjuvant chemotherapy with a combination of vinorelbine and epirubicin in locally advanced breast cancer: Preliminary results of a Phase II study [meeting abstract]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology; 1997 May 17-20; Denver, CO, USA. Alexandria, VA: ASCO; 1997. A587.
252. Fety R, Vernillet L, Perrocheau G, Vergniol JC, Puozzo C, Zorza G, et al. Pharmacokinetic study of docetaxel (D) plus vinorelbine (V) combination as first line CT in patients with MBC [meeting abstract]. Proceedings of the 87th Annual Meeting of the American Association for Cancer Research; 1996 Apr 20-24; Washington, DC, USA. Philadelphia, PA: AACR; 1996. p. 183.
253. Frassoldati A, Banzi M, Federico M, Sabbatini R, Barbieri F, Silingardi V. EVITA, a new dose-dense sequential chemotherapy combination for advanced breast cancer [meeting abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta, GA, USA. Alexandria, CA: ASCO; 1999. A503.
254. Fumoleau P, Canobbio L, Marty M, Belpomme D, Delgado FM. Phase II studies with Navelbine vinorelbine (NVB) in advanced breast cancer (ABC). J Cancer Res Clin Oncol 1990;116 Suppl 2:1052.
255. Fumoleau P, Delecroix V, Perrocheau G, Borg-Olivier O, Louboutin C, Fety R, et al. Docetaxel (D) in combination with vinorelbine (V) as 1st line CT in Pts with MBC: Preliminary results on 22 entered Pts. Breast Cancer Res Treat 1996;37 Suppl:91.
256. Fumoleau P, Delecroix V, Perrocheau G, Maugard Louboutin C, Fety R. Taxanes (T) + vinorelbine (V) Phase I [meeting abstract]. Proceedings of the 6th International Congress on Anti-Cancer Treatment; 1996 Feb 6-9; Paris, France. Paris: Service d'Oncologie Medicale Pitie-Salpetriere; 1996. p. 65.
257. Fumoleau P, Deporte Fety R, Kerbrat P, Laguerre B. UFT plus oral calcium folinate/vinorelbine for advanced breast cancer. Oncology (Huntingt) 1999;13 (7 Suppl 3):86-90.
258. Gandia D, Romero Acuna L, Machiavelli M, Vallejo C, Langhi M, Cuevas M, et al. Vinorelbine (VNB)-paclitaxel (PXL)-induced rapid bone lesions remodeling in metastatic breast cancer (MBC) [meeting abstract]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology; 1997 May 17-20; Denver, CO, USA. Alexandria, VA: ASCO; 1997. A593.
259. Garcia Carbonero I, Martin M, Casado A, Lluch A, Segura PP, De Paz L, et al. Paclitaxel plus vinorelbine in metastatic breast cancer patients with contraindications to receive anthracyclines: Preliminary results of a Phase II study. Eur J Cancer 1998;34 Suppl 2:S4.
260. Gardillou L, Cvitkovic F, Floiras JL, Briere M, Turpin F. Acute pancreatitis following cytotoxic therapy based on doxorubicin and vinorelbine: About a case report. J Pharm Clin 1999;18:292-4.
261. Gardin G, Pronzato P, Gasco M, Tognoni A, Vigani A, Vaira F, et al. Intensified regimen with paclitaxel and vinorelbine in metastatic breast cancer (MBC): A Phase II study. Breast Cancer Res Treat 1997;46:97.
262. Gardin G, Pronzato P, Tognoni A, Vigani A, Vaira F, Gasco M, et al. A Phase II trial of vinorelbine (V) and paclitaxel (P) in patients with metastatic breast cancer (MBC) who have failed prior anthracycline containing chemotherapy [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 15-18; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A542.
263. Gasco M, Gardin G, Repetto L, Campora E, Rosso R. Vinorelbine as palliative therapy in advanced breast cancer. Anticancer Res 1997;17:1431-3.
264. Gasmi J, Boutan Laroze A, Urbajtel M, Pouliquen X, Vacher B, Tiqui C. Phase II study of concomitant chemo-radiotherapy after neo-adjuvant chemotherapy for patients (pts) with locally advanced breast cancer (LABC) [meeting abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta, GA, USA. Alexandraia, VA: ASCO; 1999. A334.
265. Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB, et al. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: A Phase II study. J Clin Oncol 1994;12:2094-101.
266. Gebbia V, Mauceri G, Fallica G, Borsellino N, Tirrito ML, Testa A, et al. Pegylated liposomial doxorubicin with escalating dose vinorelbine in metastatic breast carcinoma: A dose finding study [meeting abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta, GA, USA. Alexandria, VA: ASCO; 1999. A811.
267. Gorzegano G, Berruti A, Sperone P, Bottini A, Lorusso V, Brunelli A, et al. Phase II study of vinorelbine with protracted 5-fluorouracil infusion as a second-third line approach for advanced breast cancer patients previously terated with anthracyclines [meeting abstract]. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology; 2000 May 20-23; New Orleans, LA, USA. Alexandria, VA: ASCO; 2000. A447. URL: http://www.asco.org/cgi-bin/prof/abst00.pl?absno=447&div=bc&year= 00abstracts
268. Graif C, Manente P, Stocker J, Amor H, Nelli P, Vicario G. A randomized Phase II trial of two different schedules of mitomycin-C and vinorelbine in pretreated breast cancer. Ann Oncol 1996;7 Suppl 5:27.
269. Gunel N, Akcali Z, Uner A, Yamac D, Turner F, Coskun U. Cisplatin plus vinorelbine as a salvage regimen in refractory breast cancer [meeting abstracts]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta, GA, USA. Alexandria, VA: ASCO; 1999. A505.
270. Gunel N, Akcali Z, Yamac D, Onuk E, Yilmaz E, Bayram O, et al. Cisplatin plus vinorelbine as a salvage regimen in refractory breast cancer. Tumori 2000;86:283-5.
271. Harris Spiridonidis C. Vinorelbine tartrate. Drugs Today 1992;28:160-2.
272. Havlin K. A Phase I/Phase II trial of granulocyte colony-stimulating factor as bone marrow support in patients treated with vinorelbine (Navelbine): Study design and goals. Semin Oncol 1995;22(2 Suppl 5):38-40.
273. Hoff PM, Valero V, Ibrahim N, Willey J, Hortobagyi GN. Hand-foot syndrome
274. Hortobagyi G.N. Summary of clinical results of vinorelbine (Navelbine (R)) in the treatment of breast cancer. In: Breast Cancer: Advances in Biology and Therapeutics. Montrouge: John Libbey Eurotext; 1996. p. 251-6.
275. Ibrahim NK, Hortobagyi GN, Valero V, Walters R, Willey J, Buzdar AU. Phase I study of vinorelbine (NVB; Navelbine) and paclitaxel (PTX; Taxol) by simultaneous (sim) 3-hour (H) infusion (inf), with G-CSF support, for untreated metastatic breast cancer (MBC). Breast Cancer Res Treat 1996;37 Suppl:44.
276. Ibrahim NK, Hortobagyi GN, Valero V, Theriault R, Willey J. Phase I study of Navelbine (vinorelbine, VNR) administered by 96-hour (H) infusion (I) in metastatic breast cancer (MBC) patient (pts) [meeting abstract]. Proceedings of the 19th Annual San Antonio Breast Cancer Symposium on Breast Cancer Research and Treatment; 1996 Dec 11-14; San Antonio, TX, USA. p. 287.
277. Ibrahim NK, Willey J, Rahman Z, Valero V, Hortobagyi GN. Phase II study of vinorelbine (VNR) by 96-hour (H) continuous infusion (CI) for patients (PTS) with metastatic breast cancer (MBC) [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 15-18; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A436.
278. Ibrahim NK, Rahman Z, Valero V, Willey J, Theriault RL, Buzdar AU, et al. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer 1999;86:1251-7.
279. Ibrahim NK, Sahin AA, Dubrow RA, Lynch PM, Boehnke Michaud L, Valero V, et al. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet 2000;355:281-3.
280. Ionta MT, Murru R, Scanu A, Atzori F, Massidda B. Cisplatin-based chemotherapy: A disproportionate myelotoxic effect [meeting abstract]. Proceedings of the 7th International Conference on Adjuvant Therapy of Primary Breast Cancer; 2001 Feb 21-24; St Gallen, Switzerland. Camperdown, New South Wales: National Breast Cancer Centre; 2001. S30.
281. Jaremtchuk A, Matwiejuk M, Polera O, Lozano M, Gil Deza E, Muro H, et al. Feasibility study of the combination Navelbine (N) and paclitaxel (PCL) in advanced breast cancer (ABC) [meeting abstract]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology; 1997 May 17-20; Denver, CO, USA. Alexandria, VA: ASCO; 1997. A614.
282. Jiang Z, Song S, Xu J. Navelbine as a single agent to treat advanced breast cancers. Zhonghua Zhong Liu Za Zhi 1996;18:208-10.
283. Joel S. The comparative clinical pharmacology of vincristine and vindesine: Does vindesine offer any advantage in clinical use? Cancer Treat Rev 1995;21:513-25.
284. Kardinal CG, Cole JT, Gralla RJ, Rivera NP, Rittenberg CN. Navelbine (vinorelbine) and mitomycin C: Combination therapy in advanced breast cancer [meeting abstract]. Proceedings of the 31st Annual Meeting of the American Society of Clinical Oncology; 1995 Mar 20-23; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1995. A225.
285. Kariya S, Ogawa Y, Nishioka A, Terashima M, Yoshida S, Inomata T. Effect of the docetaxel (TXT)-cisplatin (CDDP) therapy in patients with CAF resistant recurrent (metastatic) breast cancer. Jpn J Clin Radiol 2000;45:1643-7.
286. Kayitalire L, Spielman M, Brain E, Sari C, Le Cesne A, Toussaint C, et al. Salvage chemotherapy (CT) with combination of mitoxantrone (MTZ) and vinorelbine (VRB) in resistant to anthracyclines advanced breast cancer (ABC) [meeting abstract]. Proceedings of the 29th Annual Meeting of the American Society of Clinical Oncology; 1993 May 16-18; Orlando, FL, USA. Alexandria, VA: ASCO; 1993. A161.
287. Kennedy MJ, Huelskamp AM, Clarke BV, Davidsn NE, Fetting JH, Abeloff MD. Phase I evaluation of the incorporation of vinorelbine into dose-intense multi-agent regimens for the treatment of metastatic breast cancer [meeting abstract]. Proceedings of the 32nd Annual Meeting of the American Society of Clinical Oncology; 1996 May 18-21; Philadelphia, PA, USA. Alexandria, VA: ASCO; 1996. A90.
288. Koriech OM, Mughal TI. Phase II study of vinorelbine and mitomycin-C in advanced breast cancer [meeting abstract]. Proceedings of the 31st Annual Meeting of the American Society of Clinical Oncology; 1995 Mar 20-23; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1995. A251.
289. Kourousis C, Kakolyris S, Androulakis N, Heras P, Vlachonicolis J, Vamvakas L, et al. Salvage chemotherapy with paclitaxel, vinorelbine, and cisplatin (PVC) in anthracycline-resistant advanced breast cancer. Am J Clin Oncol 1998;21:226-32.
290. Laufman LR, Spiridonidis CH, Jones JJ, Rhodes VA, Wallace K. Phase I trial of doxil plus vinorelbine (VNB) in patients (PTS) with advanced malignancies [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 15-18; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A944.
291. Leonard R, Anderson L. A systematic review of docetaxel, paclitaxel and vinorelbine in the treatment of advanced breast cancer in the UK [meeting abstract]. Proceedings of the 36th Annual Meeting of the American Society of Clinical Oncology; 2000 May 20-23; New Orleans, LA, USA. Alexandria, VA: ASCO; 2000. A457.
292. Lepine M, Delorme J, Nicoara A, Guillet P, Favre R, Braguer D. G-CSF in ≪ modified AVCF ≫ protocol for breast cancer: Clinical and cost evaluation. J Pharm Clin 1999;18(Special Issue):22-4.
293. Linke Z, Kubackova K, Prausova J. Docetaxel in the treatment of breast cancer in the Department of Radiotherapy and Oncology, Faculty Hospital Motol. Klin Onkol 2000;13:22-6.
294. Livingston RB, Ellis GK, Williams MA. Weekly vinorelbine (Navelbine, NVB) + GCSF in Taxol-refractory metastatic breast cancer (MBC): A Phase I-II study [meeting abstract]. Proceedings of the 31st Annual Meeting of the American Society of Clinical Oncology; 1995 Mar 20-23; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1995. A138.
295. Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997;15:1395-400.
296. Lokich JJ, Anderson N, Bern M, Coco F, Dow E. The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen: A Phase I-II study of paclitaxel, cisplatin, and vinorelbine. Cancer 1999;85:499-503.
297. Lombardi D, Magri MD, Crivellari D, Spazzapan S, Paolello C, De Cicco M, et al. Combination chemotherapy with Navelbine and continuous infusion of 5-fluorouracil in metastatic, chemotherapy refractory breast cancer. Ann Oncol 2000;11:1041-3.
298. Louboutin JP, Fumoleau P, Maugard Louboutin C, Perrocheau G, Borg Olivier O, Gentin M, et al. A Phase I dose finding study of docetaxel (D) in combination with vinorelbine (V): An evaluation of the neurotoxicity in metastatic breast cancer (MBC) patients [meeting abstract]. Proceedings of the 87th Annual Meeting of the American Association for Cancer Research; 1996 Apr 20-24; Washington, DC, USA. Philadelphia, PA: AACR; 1996. A1155.
299. Maisano R, Adamo V, Toscano G, Chiofalo G, Pergolizzi S, Scimone A. Defibrotide in the prevention of venous irritation by vinorelbine administration. Anticancer Res 1997;17:2775-7.
300. Martin M, Carbonero IG, Lluch A, Casado A, Paz LD, Segura PP, et al. Paclitaxel plus vinorelbine: An active regimen in metastatic breast cancer patients with prior anthracycline exposure [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 15-18; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A604.
301. Martin M, Casado A, Perez Segura P, Garcia Carbonero I, Diaz Rubio E. Paclitaxel plus vinorelbine in metastatic breast cancer patients with contraindications to receive anthracyclines. Oncology (Huntingt) 1998;12(1 Suppl 1):28-30.
302. Marty M, Leandri S, Extra JM, Espie M, Besenval M. A Phase II study of vinorelbine (NVB) in patients (PTS) with advanced breast cancer (BC) [meeting abstract]. Proceedings of the 80th Annual Meeting of the American Association for Cancer Research; 1989 May 24-27; San Francisco, CA, USA. Philadelphia, PA: AACR; 1989. p. 256.
303. McGuirt C, Conklin HS, Jewett MJ, Orban BS, Deangelis DV, Weissinger H, et al. An open-label, compassionate plea study of IV Navelbine (NVB) in anthracycline and taxane-refractory metastatic breast cancer patients. Breast Cancer Res Treat 1996;37 Suppl:75.
304. Michelotti A, Gennari A, Salvadori B, Giannessi PG, Baldini E, Tibaldi C, et al. Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients. Semin Oncol 1996;23(5 Suppl 11):38-40.
305. Michelotti A, Gennari A, Salvadori B, Tognoni A, Tibaldi C, Baldini E, et al. Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: A Phase II study. Ann Oncol 1996;7:857-60.
306. Michl I, Kornek G, Depisch D, Pirker R, Liebhard A, Schenk T, et al. Phase II study of Navelbine plus mitomycin C as salvage therapy for metastatic breast cancer. Ann Hematol 1992;65:A15.
307. Minchella I, Colleoni M, Orvieto E, Nole F, Viale G, Fazio N, et al. Prediction of response to primary chemotherapy (PCT) for operable breast cancer [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 15-18; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A2114.
308. Minchella I, Colleoni M, Nole F, Sarti M, Catania C, Ullrich B, et al. Primary chemotherapy in operable or locally advanced breast cancer (OLABC) using a regimen containing vinorelbine (V), cisplatin (P) and continuous infusion of fluorouracil (FUci) [meeting abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta, GA, USA. Alexandria, VA: ASCO; 1999. A516.
309. Moiseyenko V, Orlova R, Ermakova N, Procenko S, Mikchajlithenko T, Semjonova A. Efficacy and toxicity of some chemotherapeutic regimes in heavily pretreated anthracycline-resistant metastatic breast cancer (ARMBC). Eur J Cancer 1999;35 Suppl 4:S328.
310. Mouret-Reynier MA, Cure H, Brain E, Charrier S, Penault-Llorca F, Van Praagh I, et al. TNCF regimen as neo-adjuvant chemotherapy allowing a high pathological response rate for high risk operable breast cancer: Updated data with long term results. Breast Cancer Res Treat 1999;57:68.
311. Mustacchi G, Ceccherini R, Muggia N, Milani S, Amoroso V, Fosser V. Cisplatinum and vinorelbine (CV) in metastatic breast cancer (MBC) after anthracycline failure [meeting abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta, GA, USA. Alexandria, VA: ASCO; 1999. A518.
312. Mustafa M, Walsh G, Smith IE, Johnston SRD. Vinorelbine; An active and well tolerated treatment for anthracycline pre-treated metastatic breast cancer [meeting abstract]. Br J Cancer 1999; 80 Suppl 2:103.
313. Niitani H, Furuse K, Fukuoka M, Hasegawa K, Taguchi T. Phase I clinical study on new vinca alkaloid derivative, KW-2307 (vinorelbine). KW-2307 Study Group. Gan To Kagaku Ryoho 1994;21:177-87.
314. Nistico C, Matteis AD, Valenza R, Quattrocchio D, Garufi C, Cremonesi M, et al. Epirubicin (EPI) and vinorelbine (VNR): A new promising combination for primary systemic chemotherapy for breast cancer patients (PTS) [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 15-18; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A622.
315. Nistico C, Ranuzzi M, Pace A, Bove L, Tropea F, Cardamone I, et al. Weekly vinorelbine in previously treated patients with advanced breast cancer: Preliminary results [meeting abstract]. Proceedings of the 31st Annual Meeting of the American Society of Clinical Oncology; 1995 Mar 20-23; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1995. A181.
316. Nistico C, Garufi C, Milella M, Vaccaro A, D'Ottavio AM, Fabi A, et al. Weekly schedule of vinorelbine in pretreated breast cancer patients. Breast Cancer Res Treat 2000;59:223-9.
317. Nole F, De Braud F, De Pas M, Rotmensz N, Aapro MS. A Phase II study of Navelbine (NVL) and fluorouracil plus folinic acid (FU/FA) in patients with metastatic breast cancer [meeting abstract]. Proceedings of the 6th International Congress on Anti-Cancer Treatment; 1996 Feb 6-9; Paris, France. Paris: Service d'Oncologie Medicale Pitie-Salpetriere; 1996. p. 69.
318. Nole F, De Braud F, Munzone E, Fazio N, Minchella I, De Pas T, et al. Phase I/II study of vinorelbine (VRLB) in combination with 5-fluorouracil and folinic acid (FUFA) in metastatic breast cancer [meeting abstract]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology; 1997 May 17-20; Denver, CO, USA. Alexandria, VA: ASCO; 1997. A648.
319. Nole F, Munzone E, Zampino MG, Minchella I, Colleoni M, Noberasco C, et al. Continuous infusion of 5-fluorouracil (ciFU) given with vinorelbine (Vi) and cisplatin (P) (ViFUP) in heavily pretreated metastatic breast cancer (MBC). Eur J Cancer 1998;34 Suppl 2:S7.
320. Nole F, Minchella I, Colleoni M, Orvieto E, Munzone E, De Braud F, et al. Primary chemotherapy in operable breast cancer with favorable prognostic factors: A pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN). Ann Oncol 1999;10:993-6.
321. Nole F, Catania C, Mandala M, Zampino MG, Munzone E, Ferretti G, et al. Phase I study of vinorelbine (V) and capecitabine (C) in advanced breast cancer (ABC) [meeting abstract]. Proceedings of the 23rd Annual San Antonio Breast Cancer Symposium on Breast Cancer Research and Treatment; 2000 Dec 6-9; San Antonio, TX, USA. p. 125.
322. O'Shaughnessy J, Horton J, Perez EA, Muss HB. Salvage chemotherapy for metastatic breast cancer. Cancer Control 1999;6 (5 Suppl.):22-7.
323. Ozguroglu M, Demir G, Demirelli F, Molinas Mandel N, Buyukunal E, Serdengecti S, et al. Vinorelbine plus infusional 5-fluorouracil in anthracycline and taxane refractory metastatic breast cancer: A pilot study. J Buon 1999;4:367-72.
324. Pan Z, Yan Z, Xie G. A clinical random study on combination of navelbine and fluorouracil plus leucovorin and combination of epirubicine and methotrexate for advanced and metastatic breast cancer. Zhongguo Zhongliu Linchuang 2000;27:769-72.
325. Peacock NW, Burris HA, Dieras V, Smith L, Rodriguez GI, Eckardt JR, et al. A Phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors. Invest New Drugs 1998;16:37-43.
326. Pienkowski T, Gruszfeld AI. A pilot study of docetaxel (D) and vinorelbine (V) in metastatic breast cancer (MBC) [meeting abstract]. Proceedings of the 23rd Annual San Antonio Breast Cancer Symposium on Breast Cancer Research and Treatment; 2000 Dec 6-9; San Antonio, TX, USA. p. 83.
327. Pronzato P, Queirolo P, Landucci M, Vaira F, Vigani A, Gipponi M, et al. Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer. Breast Cancer Res Treat 1997;42:183-6.
328. Pronzato P, Tognoni A, Pensa F, Vaira F, Vigani A. A dose finding study for the combination of epidoxorubicin and vinorelbine, delivered every two weeks with G-CSF support, in advanced breast cancer. J Chemother 1998;10:326-30.
329. Provencio M, Navarro F, Villanueva MJ, Sanchez A, Cubedo R, Bonilla F, et al. Phase II clinical trial of a new vinorelbine (VNB) schedule in metastatic breast carcinoma [meeting abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta, GA, USA. Alexandria, VA: ASCO; 1999. A522.
330. Queiber W, Doss A. Safety and tolerance of navelbine (vinorelbine). J Cancer Res Clin Oncol 1990;116 Suppl 2:1051.
331. Raderer M, Kornek G, Hejna M, Vorbeck F, Weinlaender G, Scheithauer W. Acute pulmonary toxicity associated with high-dose vinorelbine and mitomycin C. Ann Oncol 1996;7:973-5.
332. Ranuzzi M, Nistico C, Garufi C, Izzo F, Tropea F, Venturo I, et al. Vinorelbine (VNR) in weekly schedule with G-CSF in patients with advanced breast cancer (ABC) [meeting abstract]. Proceedings of the 32nd Annual Meeting of the American Society of Clinical Oncology; 1996 May 18-21; Philadelphia, PA, USA. Alexandria, VA: ASCO; 1996. A166.
333. Ray Coquard I, Biron P, Bachelot T, Guastalla JP, Catimel G, Merrouche Y, et al. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens. Cancer 1998;82:134-40.
334. Ray Coquard I, Blay JY, Bachelot T, Berton D, Guastalla JP, Catimel G, et al. Continuous IV infusion of vinorelbine (VNB) and bolus cisplatinum (CDDP) (CIVIC regimen) an efficient regimen in hormone-resistant metastatic breast cancers (MBC), after failure of anthracycline and/or paclitaxel [meeting abstract]. Proceedings of the 31st Annual Meeting of the American Society of Clinical Oncology; 1995 Mar 20-23; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1995. A248.
335. Robieux I, Sorio R, Vitali V, Freschi A, Cannizzaro R, Borsatti E, et al. Pharmacokinetics of vinorelbine in breast cancer patients with liver metastases [meeting abstract]. Proceedings of the 31st Annual Meeting of the American Society of Clinical Oncology; 1995 Mar 20-23; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1995. A1473.
336. Robieux I, Sorio R, Borsatti E, Cannizzaro R, Vitali V, Aita P, et al. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 1996;59:32-40.
337. Saeki T, Adachi I, Ogita M, Tabei T, Shin E, Tamura K, et al. Combination chemotherapy with vinorelbine and other cytotoxic agents for advanced breast cancer patients: A protocol of vinorelbine plus AC regimens used by the Japan Vinorelbine Study Group. Gan To Kagaku Ryoho 2000;27:1180-4.
338. Shamseddine AI, Taher A, Dabaja B, Dandashi A, Salem Z, El Saghir NS. Combination cisplatin-vinorelbine for relapsed and chemotherapy-pretreated metastatic breast cancer. Am J Clin Oncol 1999;22:298-302.
339. Shparyk I. Retrospective analysis of dose intensity in neoadjuvant chemotherapy of breast cancer. Br J Cancer 1997;76 Suppl 1:42.
340. Sorio R, Robieux I, Galligioni E, Freschi A, Colussi AM, Crivellari D, et al. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 1997;33:301-3.
341. Tagliabue P, Mariani G, Brambilla C, Demicheli R, Marchiano A, Gianni L, et al. Dose-finding study of gemcitabine (G) plus vinorelbine (V) in metastatic breast cancer (MBC) [meeting abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta, GA, USA. Alexandria; VA: ASCO; 1999. A423.
342. Tamelini WA, Fialho SA, Silva RM, Oliveira EE. Brigadeiro Hospital experiment for treatment of patients with metastatic breast carcinoma, refractive or with no indication for anthracyclines chemotherapy scheme association of Navelbine (NVB) and 5-fluorouracil. In: Moraes M, Brentani R, Bevilacqua R, editors. Proceedings of the 17th Union Internationale Contre le Cancer International Cancer Congress; 1998 Aug 23-28; Rio de Janeiro, Brazil. Bologna: Monduzzi Editore; 1998. p. 817-23.
343. Tassinara D, Sartori G, Gianni L, Pasquini E, Rayaioli A, Raderer M, et al. Is acute dyspnoea a rare side effect of vinorelbine? Ann Oncol 1997;8:503-4.
344. Terzoli E, Nistico C, Ranuzzi M, Pace A, Marsella A, Bove L, et al. Weekly epirubicin plus vinorelbine in advanced breast cancer: Preliminary results [meeting abstract]. Proceedings of the 31st Annual Meeting of the American Society of Clinical Oncology; 1995 Mar 20-23; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1995. A180.
345. Terzoli E, Nistico C, Ranuzzi M, Barni S, Pace A, Izzo F, et al. Weekly epirubicin (E) plus vinorelbine (V) and G-CSF in advanced breast cancer (ABC): An active treatment. Breast Cancer Res Treat 1996;37 Suppl:46.
346. Terzoli E, Nistico C, Fabi A, D'Ottavio AM, Milella M, Vaccaro A, et al. Single-agent vinorelbine in pretreated breast cancer patients: Comparison of two different schedules [meeting abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta, GA, USA. Alexandria, VA: ASCO; 1999. A526.
347. Tominaga T, Nomura Y, Adachi I, Takashima S, Kimura M, Koyama H, et al. Early Phase II study of KW-2307 in advanced or recurrent breast cancer. KW-2307 Cooperative Study Group (Breast Cancer Section). Gan To Kagaku Ryoho 1994;21:801-8.
348. Tominaga T, Nomura Y, Adachi I, Aoyama H, Nagao K, Mitsuyama S, et al. Late Phase II study of KW-2307 in advanced or recurrent breast cancer. KW-2307 Cooperative Study Group (Breast Cancer Section). Gan To Kagaku Ryoho 1994;21:809-16.
349. Tominaga T, Hirata K, Kunii Y, Kimura M, Aoyama H, Tohge T, et al. Phase I study of vinorelbine (VRB) in combination with fluorouracil (5-FU) for advanced or recurrent breast cancer. In: Moraes M, Brentani R, Bevilacqua R, editors. Proceedings of the 17th Union Internationale Contre le Cancer International Cancer Congress; 1998 Aug 23-28; Rio de Janeiro, Brazil. Bologna: Monduzzi Editore; 1998. p. 799-801.
350. Tortoriello A, Facchini G, Caponigro F, Santangelo M, Benassai G, Persico G, et al. Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat 1998;47:91-7.
351. Tres A, Iniguez C, Larrode P, Isla D, Gonzalez P, Adelantado S, et al. Neurotoxicity of the combination of docetaxel and vinorelbine is tolerable and reversible [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 15-18; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A976.
352. Tresca P, Fumoleau P, Roche H, Pinon G, Serin D, Marie FN, et al. Vinorelbine a new active drug in breast carcinoma results of an artac Phase II trial. Breast Cancer Res Treat 1990;16:161.
353. Tueni E, Dodion P, Piccart M, Wery F, Kerger J, Delgado M. A new oral Phase I trial with Navelbine (NVB) administered on a weekly schedule [meeting abstract]. Proceedings of the 81st Annual Meeting of the American Association for Cancer Research; 1990 May 23-26; Washington, DC, USA. Philadelphia, PA: AACR; 1990. p. 207.
354. Van Cantfort J, Cano JP, Focan C, Favre R, Krikorian A, Delgado FM. Systemic bioavailability and pharmacokinetic of orally administered Navelbine (NVB) pilot study. Invest New Drugs 1989;7:460.
355. Van Praagh I, Leduc B, Feillel V, Cure H, Bichoffe A, Charrier S, et al. Neoadjuvant VEM chemotherapy regimen for operable breast cancer: Results of a cooperative study on 69 patients [meeting abstract]. Proceedings of the 31st Annual Meeting of the American Society of Clinical Oncology; 1995 Mar 20-23; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1995. A242.
356. Variol P, Puozzo C, Chevallier B, Focan C, L RM, Breillout F, et al. Pharmacokinetics of oral vinorelbine in women with advanced breast cancer [meeting abstract]. Proceedings of the 87th Annual Meeting of the American Association for Cancer Research; 1996 Apr 20-24; Washington, DC, USA. Philadelphia, PA: AACR; 1996. A1229.
357. Vici P, Di Lauro L, Carpano S, Amodio A, Pignatti F, Casali A, et al. Vinorelbine and mitomycin C in anthracycline-pretreated patients with advanced breast cancer. Oncology 1996;53:16-18.
358. Vogel C, O'Rourke M, Weber B, Jones S, Winer E, Bigley J, et al. The safety of IV Navelbine in elderly patients with advanced breast cancer (ABC) [meeting abstract]. Proceedings of the 17th Annual San Antonio Breast Cancer Symposium on Breast Cancer Research and Treatment; 1994 Dec 8-10; San Antonio, TX, USA. p. 36.
359. Wang T, Liu S, Zhang L. Efficacy and toxicity of vinorelbine as a single agent for breast cancer. Zhongguo Zhongliu Linchuang 2000;27:282-4.
360. Wei G, Yunfeng Z, Di D, et al. A clinical analysis of the effects of the combination chemotherapy with NVB malignant tumors. Acta Acad Med Hubei 2000;21:336-8.
361. Weiselberg L, Budman DR, O'Mara V, Lichtman SM, Schuster M, Buchbinder A, et al. Phase I trial of sequential vinorelbine-paclitaxel in patients with metastatic breast cancer: Early evidence of tolerability and efficacy [meeting abstract]. Proceedings of the 32nd Annual Meeting of the American Society of Clinical Oncology; 1996 May 18-21; Philadelphia, PA, USA. Alexandria, VA: ASCO; 1996. A54.
362. Weiss J, Wellens W. The addition of human albumin to vinorelbine solution prevents venous irritation. Onkologie 1999;22:416-18.
363. Willey J, Ibrahim NK, Walters R, Rahman Z, Valero V, Estern FJ, et al. Vocal cord paralysis secondary to biweekly vinorelbine (NVB; Navelbine) and paclitaxel (PTX; Taxol) by simultaneous 3-hour (H) infusion (inf) with G-CSF support as frontline therapy for metastatic breast cancer (MBC) patients (PTS) [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 15-18; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A704.
364. Zambetti M, Mariani G, Demicheli R, Valagussa P, Tomasic G, Greco M, et al. High incidence of pathological complete remissions following sequential primary chemotherapy (PC) in unfavorable locally advanced breast cancer (LABC) [meeting abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta, GA, USA. Alexandria, VA: ASCO; 1999. A289.
365. Zelek L, Barthier S, Delford JP, Fizazi K, Spielmann M. Results of weekly vinorelbine (VNB) after failure with taxanes in advanced breast cancer (ABC). Breast Cancer Res Treat 1999;57:89.
366. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313:275-83.
367. Bruno S, Mickiewicz E, Fernandez O, Alvarez AM, Sparrow C, Teixeira ZC, et al. Phase II trial of Navelbine (NVB) in the treatment of advanced breast cancer patients. J Cancer Res Clin Oncol 1990;116 Suppl 1:33.
368. Boccardo F, Canobbio L, Pastorino G, Brema F, Resasco M, Santi L. Phase II study of Navelbine (NVB) in advanced breast cancer. Invest New Drugs 1989;7:426.
369. Delozier T, Fumoleau P, Delgado FM, Gil MA, Brune C, Keiling R, et al. Phase II trial with Navelbine (NVB) in advanced breast cancer (ABC): Preliminary results. J Cancer Res Clin Oncol 1990;116 Suppl 1:33
370. Delozier T, Delgado FM, Fumoleau P, Monnier A, Kerbrat P, Brune C, et al. Phase II trial with Navelbine (NVB) in advanced breast cancer (ABC). Breast Cancer Res Treat 1990;16:149.
371. Vogel C, O'Rourke M, Winer E, Hochster H, David H, Chang A, et al. A clinical trial of intravenous (iv) Navelbine (NVB; vinorelbine tartrate) for first line treatment of women 60 years of age or older with advanced breast cancer (ABC) [meeting abstract]. Proceedings of the 32nd Annual Meeting of the American Society of Clinical Oncology; 1996 May 18-21; Philadelphia, PA, USA. Alexandria, VA: ASCO; 1996. A70.
372. Vinorelbine/doxorubicin combination demonstrates major antitumor activity in advanced breast carcinoma. Oncology USA 1997;11:470.
373. Firat D, Baltali E, Icli F, Berk O, Uskent N, Danel P, et al. Navelbine (NVB) doxorubicin (DX) combination (D1-D8) in advanced breast carcinoma previously untreated. Eur J Gynaecol Oncol 1997;18:293.
374. Costa MA, Cabral Filho S, Correa M, Yamaguchi N, Novaes NM, Andrade CA, et al. Phase II study of sequential Navelbine (NVB) and doxorubicin (DX) for the treatment of metastatic breast cancer: Preliminary results [meeting abstract]. Proceedings of the 32nd Annual Meeting of the American Society of Clinical Oncology; 1996 May 18-21; Philadelphia, PA, USA. Alexandria, VA: ASCO; 1996. A65.
375. Cabral Filho S, Correa M, Yamaguchi N, Novaes N, Andrade C, Agnelli A, et al. Phase II study of sequential Navelbine (NVB) and doxorubicin (DX) for the treatment of metastatic breast cancer: Preliminary results. Eur J Gynaecol Oncol 1997;18:295.
376. 2, on days 1 and 8 for the management of advanced breast cancer (ABC). Eur J Cancer 1997;33 Suppl 8:S151.
377. Hochster HS. Combined doxorubicin/vinorelbine (Navelbine) therapy in the treatment of advanced breast cancer. Semin Oncol 1995;22 (2 Suppl 5):55-9.
378. Turpin F, Spielman M, Jouve M, Dorval T, Sahri C, Pouillart P, et al. Phase II trial of adriamycin and Navelbine combination in metastatic breast cancer. Breast Cancer Res Treat 1991;19:168.
379. Spielmann M, Jouve M, Turpin F, Dorval T, Pouillart P, Tursz T, et al. Pilot Phase II study with Navelbine (NVB) adriamycin (ADR) combination in advanced breast cancer (ABC). Breast Cancer Res Treat 1990;16:149.
380. Tibaldi C, Baldini E, Da Prato M, Michelotti A, Chiavacci A, Di Lieto M, et al. Epirubicin (EPI) + Navelbine (NVB) as first line chemotherapy in advanced breast cancer (ABC) patients (pts): A multicenter Phase II study [meeting abstract]. Proceedings of the 6th International Congress on Anti-Cancer Treatment; 1996 Feb 6-9; Paris, France. Paris: Service d'Oncoglogie Medicale Pitie-Salpetriere; 1996. p. 71.
381. Nistico C, Garufi C, Pace R, Galla DPG, Barni S, Frontini L, et al. Weekly epirubicin (EPI) and vinorelbine (VNR) plus G-CSF in metastatic breast cancer (MBC): High activity with a 75% survival rate at two years [meeting abstract]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology; 1997 May 17-20; Denver, CO, USA. Alexandria, VA: ASCO; 1997. A647.
382. Nistico C, Garufi C, Ranuzzi M, Barni S, Izzo F, Giunta S, et al. High activity in advanced breast cancer (ABC) with the weekly combination of epirubicin (EPI), vinorelbine (VNR) and G-CSF [meeting abstract]. Proceedings of the 32nd Annual Meeting of the American Society of Clinical Oncology; 1996 May 18-21; Philadelphia, PA, USA. Alexandria, VA: ASCO; 1996. A228.
383. Terzoli E, Nistico C, Ranuzzi M, Garufi C, Izzo F, Pualiese P, et al. G-CSF allows high dose-intensity and activity in patients with advanced breast cancer with weekly epirubicin plus vinorelbine [meeting abstract]. Proceedings of the 6th International Congress on Anti-Cancer Treatment; 1996 Feb 6-9; Paris, France. Service d'Oncologie Medicale Pitie-Salpetriere; 1996. p. 71.
384. Romero Acuna L, Langhi M, Perez J, Leone B, Machiavelli M, Lacava J, et al. Vinorelbine (VNB) and paclitaxel (PTX) as first-line chemotherapy (FLC) in metastatic breast cancer (MBC): Final results [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 15-18; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A658.
385. Romero Acuna L, Langhi M, Perez J, Leone B, Machiavelli M, Lacava J, et al. Vinorelbine (VNB) and paclitaxel (PTX) as first-line chemotherapy (FLC) in metastatic breast cancer (MBC) [meeting abstract]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology; 1997 May 17-20; Denver, CO, USA. Alexandria, VA: ASCO; 1997. A661.
386. Vici P, Conti F, Amodio A, Belli F, Della Giulia M, Mariotti S, et al. Simultaneous infusion of vinorelbine and Taxol as first-line chemotherapy in metastasized breast cancer. Clin Ter 1998;149:255-9.
387. Vici P, Amodio A, Di Lauro L, Paoletti G, Foggi P, Squilloni E, et al. Simultaneous infusion of vinorelbine (VNB) and paclitaxel (P) as first-line chemotherapy (CT) in advanced breast cancer (ABC) patients (pts) [meeting abstract]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology; 1997 May 17-20; Denver, CO, USA. Alexandria, VA: ASCO; 1997. A688.
388. Ferrero JM, Wendling JL, Hoch M, Frenay M, Francois E, Namer M. Mitoxantrone (MTZ)-vinorelbine (VNR) as first-line chemotherapy (CT) in metastatic breast cancer (MBC): A pilot study [meeting abstract]. Proceedings of the 29th Annual Meeting of the American Society of Clinical Oncology; 1993 May 16-18; Orlando, FL, USA. Alexandria, VA: ASCO; 1993. A234.
389. Spielmann M, Llombart-Cussac A, Roset A, Antoine E, Le Cesne A, Janin N, et al. Efficacy of a chemotherapy (CT) regimen combining vinorelbine (VRB) and mitoxantrone (MTZ) in advanced breast cancer (ABC) patients (Pts) resistant to anthracycline regimen. Breast Cancer Res Treat 1994;32 Suppl:33.
390. Fumoleau P, Delecroix V, Perrocheau G, Borg Olivier O, Maugard C, Fety R, et al. Clinical data of Navelbine-Taxotere association in breast cancer patients. In: Breast Cancer: Advances in Biology and Therapeutics. Montrouge: John Libbey Eurotext; 1996. p. 273-8.
391. Fumoleau P, Delecrox V, Perrocheau G, Borg Olivier O, Maugard C, Fety R, et al. Docetaxel (D) in combination with vinorelbine (V) as 1st line CT in pts with metastatic breast cancer (MBC): Final results [meeting abstract]. Proceedings of the 32nd Annual Meeting of the American Society of Clinical Oncology; 1996 May 18-21; Philadelphia, PA, USA. Alexandria, VA: ASCO; 1996. A232.
392. Penz M, Kornek GV, Ulrich-Pur H, Haider K, Kwasny W, Depisch D, et al. Treatment of advanced breast cancer (ABC) vinorelbine and docetaxel +/- human
393. Kornek GV, Ulrich-Pur H, Penz M, Haider K, Kwasny W, Depisch W, Depisch D, et al. Treatment of advanced breast cancer with vinorelbine and docetaxel + human granulocyte colony-stimulating factor. Onkologie 2000;23 Suppl 7:10.
394. Dieras V, Extra JM, Morvan F, Bellissant E, Fandi A, Espie M, et al. Phase II study of Navelbine (NVE) and fluorouracil (FU) in metastatic breast cancer (MBC) patients using a group sequential design (GSD). Breast Cancer Res Treat 1990;16:161.
395. Vogel C, Hochster H, Blumenreich M, Davis H, Graham M, Fabian C, et al. A US multicenter Phase II study of iv Navelbine (NVB) and 5-fluorouracil (5FU) as first line treatment of patients with advanced breast cancer (ABC) [meeting abstract]. Proceedings of the 31st Annual Meeting of the American Society of Clinical Oncology; 1995 Mar 20-23; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1995. A62.
396. Ardavanis A., Extra JM, Espie C, Cuvier C, Marty M. Phase II trial of a combination of vinorelbine (VNB), cyclophosphamide (CPA) and 5-fluorouracil (FU) in the treatment of advanced breast cancer. Eur J Gynaecol Oncol 1997:18:294.
397. Leone B, Vallejo C, Romero A, Perez J, Cuevas M, Lacava J, et al. Ifosfamide (IFX) and vinorelbine (VNB) as first-line chemotherapy (FLC) for metastatic breast cancer (MBC): Final results [meeting abstract]. Proceedings of the 32nd Annual Meeting of the American Society of Clinical Oncology; 1996 May 18-21; Philadelphia, PA, USA. Alexandria, VA: ASCO; 1996. A74.
398. Leone B, Vallejo C, Romero A, Perez J, Cuevas M, Lacava J, et al. Ifosfamide (IFX) and vinorelbine (VNB) as first-line chemotherapy (FLC) for metastatic breast cancer (MBC) [meeting abstract]. Proceedings of the 31st Annual Meeting of the American Society of Clinical Oncology; 1995 Mar 20-23; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1995. A187.
399. Nole F, Munzone E, Orlando L, Michella I, Zampino MG, Colleoni M, et al. First line chemotherapy for metastatic breast cancer (MBC): A regimen with a low subjective toxic burden containing vinorelbine (V), continuous infusion 5-fluorouracil (ci FU) and cisplatin (P) (ViFuP) [meeting abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta, GA, USA. Alexandria, VA: ASCO; 1999. A429.
400. Ejlertsen B. Phase III randomized study of epirubicin/vinorelbine vs epirubicin alone for advanced breast cancer [monograph online]. In: PDQ. Bethesda, MD: National Cancer Institute; 1996. [cited 2000 Sep 30]. URL http://cancernet.nci.nih.gov/trialsrch.shtml
401. Sith IE. Phase II randomised study of vinorelbine/epirubicin versus vinorelbine/mitoxantrone versus cyclophosphamide/doxorubicin as preoperative chemotherapy in women with early stage breast cancer [monograph online]. In: PDQ. Bethesda, MD: National Cancer Institute; 2000. [cited 2000 Sep 30]. URL http://cancernet.nci.nih.gov.trialsrch.shtml
402. Kerbrat P. Phase III randomized study of adjuvant fluorouracil/epirubicin/cyclophosphamide vs epirubicin/vinorelbine in women with high-risk node-positive breast cancer [monorgraph online]. In: PDQ. Bethesda, MD: National Cancer 1997. [cited 2000 Sep 30]. URL http://cancernet.nci.nih.gov/trialsrch.shtml
403. Brown R, Hutton J. Cost utility of Taxotere vs vinorelbine or Taxol in advanced breast cancer. Br J Cancer 2000;83 Suppl 1:48.
404. Brown R, Hutton J. Cost utility of doxetaxel vs vinorelbine or paclitaxel in advanced breast cancer. Value in Health 2000;3:49.
405. Brown RE, Hutton J, Burrell A. The cost utility of Taxotere vs. vinorelbine or Taxol for the treatment of advanced breast cancer [unpublished]. West Malling, London: Aventis, MEDTAP International Inc.: 2000.
406. Anderson L, Cox J. A systematic review of docetaxel, paclitaxel and vinorelbine in the treatment of advanced breast cancer in the UK [unpublished]. London: Anderson Cox Consulting; 2000.
407. Leonard R, Anderson L. A systematic review of docetaxel, paclitaxel and vinorelbine in the treatment of advanced breast cancer in the UK [unpublished]. London: Anderson Cox Consulting; 2000.
408. Ten Bokkel Huinink WW, Prove AM, Piccart M, Stewart W, Tursz T, Wanders J, et al. A Phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer; A study of the EORTC Early Clinical Trials Group. Ann Oncol 1994;5:527-32.
409. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, et al. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-94.
410. Ravdin PM, Burris HA IIIrd, Cook G, Eisenberg P, Kane M, Bierman WA, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-85.
411. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Clavel M, Seeber S, et al. Randomized trial of two doses of Taxol in metastatic breast cancer: An interim analysis [meeting abstract]. Proc Annu Meet Am Soc Clin Oncol 1993;12:A42.
412. Food and Drug Administration Center for Drug Evaluation and Research Oncologic Drugs Advisory Committee. Study 048: Multicentric Randomized Study of Two Doses of Taxol in Metastatic Breast Cancer. Rockville, MD; FDA; 1993. Report No.: 048F01-F017. CH3.
413. Leung P, Dranitsaris G, Puodziunas A, Tannock I, Oza A. Cost utility analysis of second line chemotherapy in anthracycline resistant breast cancer: Paclitaxel versus docetaxel versus vinorelbine [meeting abstract]. Proceedings of the 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta, GA, USA. Alexandria, VA: ASCO; 1999. A1617.
414. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, et al. Multi-center, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-67.
415. Nabholtz JM, Thuerlimann B, Beswoda WR, Melnychuk D, Deschenes L, Douma J, et al. Taxotere (T) improves survival over mitomycin C vinblastine (MV) in patients (PTS) with metastatic breast cancer (MBC) who have failed an anthracycline (ANT) containing regimen: Final results of a Phase III randomized trial [meeting abstract]. Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 15-18; Los Angeles, CA, USA. Alexandria, VA: ASCO; 1998. A390.